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ABSTRACT 
 
 
Rett syndrome (RTT) is a rare progressive neurodevelopmental disorder that occurs in 
1:10,000-15,000 females. Normal early growth is followed by, above all, motor and 
cognitive regression. RTT is caused by mutations of the MECP2 gene, located on an X-
chromosome and subject to random inactivation, that generates a very variable 
phenotype. Methyl-CpG-binding protein-2 (MeCP2) is a transcriptional factor involved 
in brain connectivity, neural circuits and – importantly - in synaptic plasticity and deficits. 
However, the molecular mechanisms related with these defects are largely unknown.  
We previously showed that c-Jun N-terminal protein kinase (JNK), a stress-activated 
kinase, was closely involved in synaptic dysfunction related to neurodegenerative disease 
(Alzheimer’s disease and ischemic stroke) and its specific inhibition, using the cell- 
permeable D-JNKI1 peptide, led to recovery of dendritic spine structure and restoration 
of function, with rescue of cognitive deficits.  We here show for the first time that JNK 
signalling is powerfully activated in RTT mice and acts as a key modulator of synaptic 
dysfunctions. 
We used MeCP2 tm 1.1 Bird male mice (referred as Mecp2 -/y) for our investigation 
because although they do not present mosaicism they have an early-onset, most severe 
phenotype within a homogeneous genetic background. D-JNKI1 (22 mg/kg) was injected 
intraperitoneally for the first time at the third week of age then repeated after three weeks. 
Well-being and behavioural studies were done, with weekly recordings of food and water 
intake, weight and locomotor abilities. At seven weeks, mice were killed and tissues were 
processed for biochemical analysis. In the brain JNK’s preferential target, c-Jun, a nuclear 
transcription factor, was strongly activated. Repeated D-JNKI1 doses improved the 
mice’s general wellbeing. Treated mice had a rescue of motor deficits and improved 
motor coordination, as seen in Rotarod and Open Field behavioural tests. Since RTT 
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causes locomotor impairment, we checked synaptic dysfunction in the cerebellum. 
Isolating the post-synaptic region, we found that D-JNKI1 treatment rescued the levels of 
AMPA and NMDA receptors. D-JNKI1 treatment showed to bring again level of PSD95 
and Shank3 protein. In our studies focused on the inflammatory pathway triggered by 
JNK and we found activation of  astrogliosis and microgliosis, completely rescued by D-
JNKI1. 
We then moved to translational medicine to further clarify JNK’s pivotal role in RTT, 
using human RTT iPSCs (induced pluripotent stem cells). The mutant neuronal-IPSc 
presented JNK activation while isogenic control neuronal-IPSc did not.  D-JNKI1 
inhibited JNK activity and the rescue of its activation on a human model increase the 
clinical relevance of the proposed treatment.   
RTT is a rare and incurable progressive postnatal female neurodegenerative disorder and 
manipulation of the JNK pathway may offer an innovative strategy to tackle the 
syndrome. JNK plays a key role in mice and human mutated neuronal iPSC and 
consequently it is important in clinical studies. We now need to better characterize D-
JNKI1’s effect in a female mosaicist model, closer to the human phenotype. 
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INTRODUCTION 
 
1. Rett syndrome: an overview 
The Rett syndrome (RTT) is a rare neurodevelopmental disorder that occurs with an 
incidence of 1:10,000 children. RTT syndrome was originally described as a clinical 
entity by Dr. Andreas Rett, an Austrian paediatrician, that in 1966 observed two little 
patients in his waiting room with similar stereotyped hand movement1,2. After a long 
period of silence, Hagberg and colleagues increased awareness of the syndrome with a 
further description of the disorder in a group of 35 girls3. The earliest hypothesis on the 
inheritance of RTT was funded on the seemingly exclusive appearance of the disorder in 
females. These observations suggested an X-linked dominant inheritance with male 
lethality. In 1999, it was firstly demonstrated that RTT is caused by mutations of the gene 
encoding the methyl-CpG binding protein 2 (Mecp2), located in Xq284. This gene 
encodes a protein that is expressed in many mammalian tissues and, binding specifically 
methylated DNA, acts as a repressor of transcription. The MECP2 mutations are found 
in about 95% of classic RTT patients and in a lower percentage of variants cases.  In some 
rare cases, Rett can occur without known mutated gene, possibly due to changes in 
MECP2 that are not still identified. Moreover, mutations in other genes may result in 
clinical similarities overlapping with these seen in the RTT5,6, such as in CDKL5 (cyclin 
dependent kinase like 5) and in FOXG1 (forkhead box G1). RTT syndrome is caused by 
a de novo mutation not depending from the parents. Mutations can also be inherited from 
phenotypically normal mothers who have a germline mutation in the MECP2 gene4. In 
these cases, inheritance follows an X-linked dominant pattern and it is seen almost 
exclusively in females, while most males die in utero or shortly after birth7,8  
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1.1. Clinical stages of Rett syndrome 
MECP2 loss-of-function is associated with RTT. This syndrome is characterized by a 
high rate of phenotypic variability in age of onset, severity of impairments and profile of 
clinical course. To date, it has been hypothesized that this heterogeneity could be due to 
differences in MECP2 gene mutations or to the random X-chromosome inactivation. 
However, these studies have yielded conflicting results and have left unresolved the issue 
of genotype-phenotype correlations, suggesting that additional modifier genetic factors 
can be involved9.  
After a period of apparently normal early infancy, affected children show first signs of 
decline around the 6th-18th month. Typical features of the syndrome are hand stereotypies 
movements development, microcephaly, growth delay and seizures. Despite of symptoms 
variability Rett syndrome progresses though 4 stages, described below. 
The stage I is called early onset and typically begins between 6 and 18 months of age. 
Early symptoms are often very vague and nonspecific. The infant may begin to show less 
eye contact and have reduced interest in toys. There may be delays in gross motor skills 
such as sitting or crawling. Hand-wringing and decreasing head growth may occur, but 
not enough to draw attention. This stage usually lasts for a few months but can continue 
for more than a year.  
The Stage II, or the rapid deterioration or regression stage, usually begins between the 1st 
and 4th year of child’s life and may last for weeks or months. Its onset may be rapid or 
gradual; the child loses purposeful hand skills and spoken language. Breathing 
irregularities such as episodes of apnoea and hyperventilation may occur, although 
breathing usually improves during sleep. Some girls also display autistic-like symptoms 
such as loss of social interaction and communication. Walking may be unsteady and 
starting motor movements can be difficult.  
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The Stage III, or the plateau or pseudo-stationary stage, usually begins between ages 2 
and 10 and can last for years. Apraxia, motor problems, and seizures are prominent during 
this stage. However, there may be improvement in behaviour, with less irritability, in 
hand use and communication skills. Despite improvement, mental impairment and hand 
stereotypies continue. Girls are often affected by rigidity, bruxism, motor dysfunction and 
seizures. Episodes of hyperventilation or breath holding may continue.  Many girls remain 
in this stage for most of their lives.  
The stage IV, or the late motor deterioration stage, can last for years or decades. 
Prominent features include reduced mobility, scoliosis and muscle weakness, rigidity, 
spasticity, and increased muscle tone with abnormal posturing of arms, legs, or top part 
of the body. Girls who were previously able to walk may stop walking. Cognition, 
communication, or hand skills generally do not decline in stage IV. Repetitive hand 
movements may decrease and eye gaze usually improves10.  
 
Figure 1- four stages of clinical pathogenesis of Rett symptoms in human. At 6-18 months, children start 
to develop first signs of mental retardation that increase during the second stage, until 2,5 years. The third 
stage is characterized by a stationarity of condition that can get worse in the fourth stage, until they die10. 
 
Patients with Rett syndrome often survive to adulthood, however, their life expectancy is 
lower than the rest of the healthy population. The percentage of annual death for Rett 
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syndrome is estimated to be 1.2%. Approximately 25% of these deaths are due to 
peripheral nervous system disorders or to heart abnormalities11,12. 
1.2. Rett syndrome variants 
In 95% of patients are affected by classic Rett syndrome 13. In addition, five atypical 
variants at least were described, with a different degree of severity based on the 
phenotypic variability associated with MECP2 different mutations14,15. These include: 
a. The “forme fruste” shows delayed onset of symptoms than the classic form. 
Regression begins between the first and third year of life. The use of the hands is 
preserved and the characteristic stereotyped movements are less intense16,17. 
b. The Zappella variant or "preserved speech variant" (PSV) is characterized by the 
ability to formulate sentences; patients show the ability to use hands and head 
circumference is normal. They are generally overweight compared to patients with the 
classic form18. 
c. The congenital form does not follow a normal period of development, but symptoms 
appear already from the first day of life and regression occurs within the first month 
of life. most cases of congenital variant are related to mutations in the gene FOXG119. 
d. The Hanefeld variant is characterized by early onset compared to the classical form. 
Symptoms occur within the 6th month of life accompanied by seizures of varying 
severity20 and is often caused by mutations in the gene CDKL521. 
e. The late regression variant is observed rarely and is characterized by a medium mental 
retardation, followed by a regression with the appearance of the classic symptoms22. 
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1.3. Localization, structure and function of MeCP2 protein 
1.3.1. Localization  
Classic Rett is a syndrome characterized by MECP2 gene mutation, that codifies for 
MeCP2 protein (Methyl-binding CpG protein-2), expressed widely throughout the body, 
in particular in mature nerve cells of the grey matter in the central nervous system23,24, 
specifically in post-mitotic neurons. The clinical course of RTT has provided clues as to 
the role of MeCP2 in the maturation of the nervous system. RTT-associated neuronal 
dysfunction firstly manifests itself in early postnatal life, when sensory experience is 
required for the refinement of developing neuronal circuits25.  
MeCP2 was well characterized as a transcription factor involved in regulating gene 
expression, but it is also involved in neuronal morphological changes26, in excitatory-
inhibitory transmission imbalance27–30 and in short-term plasticity31 during the 
development. This observation suggests that MeCP2 might mediate some of the effects 
on synapse and neural circuit development, and that the absence of activity-dependent 
regulation of MeCP2 in RTT contributes to the ethology of this disorder25.  
The reversibility of the RTT-like phenotype upon restoration of MeCP2 and the 
catastrophic consequences of MeCP2 removal in adult mice argue that MeCP2 is not 
solely a neurodevelopmental regulator32. Moreover, removal of MeCP2 from specific 
brain regions and neuronal subtypes compromises the function of that brain region. For 
example, deletion of the MECP2 gene exclusively in the forebrain causes behavioural 
abnormalities33 — including limb clasping, impaired motor coordination, increased 
anxiety and abnormal social behaviour — but does not affect locomotor activity or 
context-dependent fear conditioning. Similarly, loss of MeCP2 from all inhibitory 
GABA-releasing neurons leads to a severe RTT-like phenotype, whereas a smaller subset 
of MeCP2-negative neurons has much milder consequences34.  
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The MeCP2 function is therefore not restricted to neuronal cells. Deletion of MeCP2 from 
glial cells has mild phenotypic consequences, which is consistent with the idea that its 
primary function is in neurons35. However, co-culture experiments have revealed that 
MeCP2 in glia has a non-cell-autonomous role in supporting the normal dendritic 
morphology of neurons. Furthermore, re-expression of MeCP2 in astrocytes completely 
rescues the breathing abnormalities observed in Mecp2-null male mice, leading to greatly 
increased survival rates36. Interestingly, wild-type microglia introduced by 
transplantation of bone marrow were reported to ameliorate some of the deficits observed 
in Mecp2-null mice37 even if involves destruction of blood brain barrier.  
1.3.2. Gene structure and protein function 
The MECP2 gene spans 76 kb in Xq28 and is composed of 4 exons; it is considered an 
housekeeping gene because it has a CpG island associated with 5’-end and is ubiquitously 
expressed. It is widely expressed in embryonic and adult tissues although expression is at 
low levels early in development.  
MECP2 has two main splice variants MeCP2_e1 and MeCP2_e2, which encode proteins 
with a different N-termini38,39 and expressed in a tissue-specific way. Moreover, MeCP2 
has a long conserved 3’UTR with multiple poly-adenylation sites, which can additionally 
generate four different transcripts (with different length, between 7,5 and 10 kb). 
MeCP2_e1 is 498 amino acids long and has a translational start site in exon 1 excluding 
exon 2 from the final protein, and is ten times more abundant in the brain. It was found 
almost in hypothalamus38,40,41. Whereas, isoform MeCP2_e2 excludes the exon 1, is 486 
amino acid long and was detected mostly in the dorsal thalamus and layer 5 of cortex40. 
The possible specific role of MeCP2_e1 in the brain is already unclear, but pathogenic 
mutation have been discovered in exon 1 of this isoform in RTT patients, while such 
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mutations have been not seen for exon 241. However, studies shown that exon 1 mutations 
may be associated with a reduction of e2 protein levels42.  
Figure 2- structure of MECP2 gene and of mecp2 proteins43. On the top is shown Mecp2_e1 isoform; 
below is shown Mecp2_e2. The two isoforms are derived from a different splicing of MECP2 gene, in the 
centre of the image:  e1 starts with exon 1 and does not contain exon 2; e2 starts with exon2 and does not 
contain exon 1. Both proteins have the same function and the same functional domain, MBD, TRD and 
CTD as described in the text. 
 
Despite from different included exons, as shown in figure 3, the two MeCP2 isoforms 
show the same amino acidic sequence and domains including: 
 three functional domains (MBD, methyl-binding domain; TRD transcriptional 
repressor domain and CTD, carboxyl-terminal domain) 
 two NLS, signals for nuclear localization.  
The methyl-binding domain (MBD) consists of 85 amino acids at the end of protein and 
is essential for binding of Mecp2 to heterochromatin44 as well as to DNA four way 
junctions45. MBD has been localized in a region within exons 3 and 4 and require A/T-
rich motifs to bind the symmetrically methylated CpG dinucleotides. Even if it requires 
only a single methylated CpG for binding DNA, MeCP2 preferentially associates with 
whole blocks of methylated CpGs46.  
The transcriptional repression domain (TRD) was described by Nan et al. and is located 
among amino acids 207-310. Its involvement in transcriptional repression occurs through 
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several mechanisms. For example, it seems to reacts with Sin3 and to recruit the histone 
deacetylase complex. The MeCP2 may also make direct contacts with the basal 
transcription machinery, such as TFIIB, leading to a deacetylase-independent repression.  
The original model of MeCP2 protein function involves deacetylation of core histones 
resulting in the compaction of the chromatin and making it inaccessible to components of 
the transcriptional machinery47,48. Surprisingly, interactions between TRD and various 
cofactors demonstrate that MeCP2 protein can read methylated CpGs differently and, 
depending on the context, mediate multiple downstream responses. It will be interesting 
to know what region of the protein are involved in recruitment of co-repressor in some 
instance and of co-activators in others. Moreover, one of two identified nuclear 
localization signals (NLS) is embedded within the TRD. The other NLS, located in 
HMGD2, between the MBD and TRD49, identified an RG (arginine-glycine) repeated 
region in HMGD2, which are known to mediate RNA-protein interactions, and MeCP2 
was shown to bind to mRNA and double-stranded siRNA independent of its MBD, 
suggesting that MeCP2 may have activity as part of a selective RNA–protein complex.  
The C-terminal domain, CTD-α and CTD-β are other chromatin binding domains. The 
CTD-α recognize methylated DNA in chromatin, while the CTD-β contains conserved 
poly-proline motifs that can bind to group II WW domain splicing factors50 (see fig. 3). 
Recent studies suggest that MeCP2 is also implicated in alternative splicing as part of an 
RNA-protein complex51 using YB1, which is an RNA-binding protein and influences 
splice site. The precise mechanisms by which MeCP2 protein directed and regulated 
various functions and interactions, remain to be elucidated. 
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Figure 3- The functions of MeCP2 protein.  MeCP2 was firstly discovered as a transcriptional repression 
protein(A) by interacting with DNA in complex with Sin3A and recruiting HDACs, it showed an 
involvement in chromatin accessibility, remodelling structure by association with histone H3 Lys9 
methyltransferase and with the Dnmt1(B) or by loop formation (D). Recently has emerged a role in 
transcriptional activation(C) binding RNA pol II complex.  
 
1.4. MECP2 modification led to the syndrome phenotype 
MECP2 mutations have been identified in 75-90% of sporadic cases and approximately 
in 50% of familial cases. Interestingly, even though almost mutations are de novo, there 
are 8 common point mutations resulting from C >T transitions in CpG island15. There are 
also cases of small deletion in correspondence of a pentanucleotide repeated (CCACC) at 
exon 4.  More than 60 distinct mutations have been identified, the majority are nonsense 
or frameshift mutations that occur throughout the gene. For example, one mutation 
(Q19X) introduces an extremely early stop codon, which is likely to be a null allele. 
Additional nonsense mutations have been found in the MBD (Y141X), between the MBD 
and TRD (R168X, Q170X, and R198X), and within the TRD (R255X, K256X, R270X, 
and R294X). A partial loss of MeCP2 function cannot be excluded, however, because 
premature stop codons within the last exon may not lead to nonsense mediated mRNA 
decay. Therefore, the possibility that premature stop codons within exon 4 may produce 
A B 
C D 
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a truncated form of the protein that retains partial function, still exists. A truncated protein 
that retains the MBD, for instance, may still be able to bind to methyl-CpG nucleotides 
and may, by solely binding upstream of potential promoter regions, at least partially 
interfere with transcription. Whether the Rett syndrome is caused by both null and 
hypomorphic alleles remains an interesting question. Missense mutations have been 
identified in regions of the gene encoding the MBD, TRD, and C-terminus of the protein. 
Three of the mutations within the MBD (R106W, R133C, and F155S) have been shown 
to reduce binding to methylated DNA by more than 100- fold. It remains to be shown 
whether missense mutations in the TRD reduce interactions with the Sin3A complex and 
whether mutations in the C-terminus, which enhances the binding of MeCP2 to 
nucleosomal DNA52,53, decrease interactions with components of the nucleosome. 
 
Figure 4- MECP2 gene and most common kind of mutation that led to a Rett syndrome phenotype 
like.  MECP2 (methyl-CpG-binding protein 2) gene structure. The positions and frequencies of the most 
common mutations that are associated with Rett syndrome in females are indicated. Image taken by 
Bienvenu et al. Nature Reviews Genetics 7, 415–426 (June 2006) | doi:10.1038/nrg1878 
 
1.5. MeCP2 mouse model  
Rett syndrome is mainly due to a partial loss of MeCP2 function, which is particularly 
expressed in brain. More than irreversible damage, its lack seems to cause a functional 
disturbance of neuronal circuits54. 
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The study of RTT arouses increasing attention, but the necessity of post-mortem human 
brain made it difficult for the availability of the material and for sample quality. 
Moreover, today is not available a cure or a treatment for RTT and, even if there is a long 
history of failure in translating findings from preclinical to clinical, it is necessary to have 
a model reproducing most of the symptoms of human disease. Experimental and 
transgenic animal models of Rett syndrome have been developed for elucidating the RTT 
onset and progression. Mouse models represent a good tool to study RTT, showing 
validity of construct (that led to analogue molecular mechanism with humans), 
reproducibility, robustness of findings and similarity with anatomical, physiological and 
behavioural phenotype. In addition, mouse models allow validating potential treatment 
strategy for human Rett.  
Mice used at this purpose have three kind of mutated allele, classifiable in this three 
groups reported below: 
a) Null alleles, with a large deletion detectable in 10% of patience (Mecp2tm1.1Bird, 
Mecp2tm1.1Jae, Mecp2tm1.1Pplt). These mice showed no signs of Mecp2 protein 
expression and developed a postnatal behavioural phenotype that resembles RTT 
synptoms55,56.  
b) Truncation or single nucleotide mutation (codon-308-C-terminal truncation). These 
mice express a truncated protein with the MBD and a portion of the TRD elements 
still intact, suggesting residual protein function56–58, they could be considered mutant 
mice. The introduction of a premature STOP codon in the mouse Mecp2 gene led to 
the expression of a protein truncated at the amino acid 308 (Mecp2308)59, as thought to 
be the case in some RTT patients presenting milder disease feature. 
c) Point mutation. These mice show missense or nonsense MECP2 mutations, including 
R106W, R133C, T158M, R168X, R255X, R270X, R294X, and R306C, account for 
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more than half of the RTT cases60. Thus, mice carrying a single nucleotide change 
in Mecp2 would represent the closest experimental model of patients with RTT. 
Table 1: Mice models of Rett syndrome. 
 
In addition to mutated mice, conditional knockout mice have also been generated and 
characterized, and the inactivation of MeCP2 in single brain areas or neuronal subtype 
generally leads to subset of typical Rett61. While numerous transgenic mice have been 
created modelling on common mutations in MeCP2, the behavioural phenotype and the 
biochemical analysis of many of these male and female is not well characterized62.  
 
 
Mouse model Phenotype Take-home message 
 Onset Survival Symptoms  
Mecp2 deletion 
6 weeks (−/y) and 
(−/−) 
10 weeks 
Ataxia, reduced motor 
activity, tremors, hind limb 
clasping 
Lack of MeCP2 causes RTT-like 
phenotypes in mice; disease onset in 
females depends upon time, not 
developmental stage 
 6 months (+/−) 
Normal 
lifespan 
Milder, variable phenotypes  
MeCP2 
truncation 
4 months 
(MeCP2308/y) 
90% 10 
months 
Progressive motor and 
activity dysfunction. 
Abnormal social interaction. 
Forepaw movements 
Truncated protein found in many 
RTT cases also produces RTT-like 
phenotypes in mice 
 
10 months 
(MeCP2308/MeCP2) 
Normal 
lifespan 
Milder, variable phenotypes  
MeECP2 point 
mutation 
6- 8 months 
Normal 
lifespan 
Small size, arrhythmia, 
increased breathing rate. 
Anxiety, motor and learning 
impairment. 
Point mutations not representative, 
but are characteristic of only a small 
part 
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2. Synapses and spine plasticity 
Synapses are connections between neurons and, because of their key role in neuronal 
transmission, in learning and in memory consolidation mechanisms, they are studied with 
increasing interest. Synapses have gradually revealed an involvement in 
neurodegenerative and psychiatric disorders, such as autism63, intellectual disability, 
schizophrenia 64, depression 65, Huntington's disease 66,67, Amyotrophic Lateral 
Sclerosis68, Parkinson's disease, epilepsy, Alzheimer's disease 69and neurodevelopment 
disorder as Rett syndrome70. 
 
Figure 5- Representation of a synapse. On the left side is showed pre-synaptic element of a neuron, 
releasing neurotransmitters stored in the vesicles. Neurotransmitters bind specific receptors located on 
post-synaptic element, in the right part of the figure, and transform chemical in electrical signals. Once 
completed their function, neurotransmitters were re-uptake or degraded by enzymes, while the electrical 
signal is transmitted to other neurons. 
 
Excitatory synapses are being well characterized in literature during years, as composed 
by a definite structure, situated on dendritic spine head. Glutamate mediates most of 
excitatory neurotransmission in the brain, acting mainly on three different receptor 
classes: NMDA (N-Methyl-D-aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) and mGluR1-8  metabotropic receptors.  
Release of glutamate from pre-synaptic terminal allows the opening of AMPAr with 
increment of Na+ e K+ currents. A short burst of high frequency is enough for generating 
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a phenomenon called long-term potentiation (LTP) often associated with long-term 
memory. This strong depolarization determinate a strengthening of excitatory synapses 
for a prolonged period and influences neuronal plasticity. The excitatory post-synaptic 
potential (EPSP) generates detachment of Mg2+ ion from NMDA receptors and their 
opening, which in turn, determinates entrance of calcium influx. Calcium currents modify 
the shape of the spine, the number of receptors located on the synapses and 
consequentially spine plasticity71. mGluRs mediates slow post-synaptic response to 
decrease neuron excitability. 
The synaptic plasticity determinates an high variability of dendritic spine morphology, 
strictly correlated with biochemical and electrical features of the compartment72.  
The variable spine shape and volume is thought to be correlated with the strength and 
maturity of each spine and many studies have shown that there is a continuum among 
spine shapes (fig. 6) 
 
Figure 6- Dendritic spine classification. In the higher part (A) the different kind of spine and a general 
classification are shown.  In the lower part (B) a dendritic Golgi stained neuron highlights the different 
kind of spines. To make easier the correspondence, each spine is correlated with a colour, the same used 
in A. 
 
Large spines, named also “memory spines,” are stable, persistent for longer periods of 
time, and are the postsynaptic side of strong excitatory synapses73,74. Mushroom spines 
have a large head connected to the parent dendrite through a narrow neck. Stubby spines 
do not have a noticeable neck and are formed usually during postnatal development75,76. 
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Conversely, thin spines have a thin, long neck, and a small bulbous head, they are highly 
mobile, unstable, and often short-lived, usually representing weak or silent synapses76. 
Because thin spines are more plastic than large ones and have the potential to become 
stable spines, they have been dubbed “learning spines” 73,74,77,78. It should be noted that 
thin protrusions longer than thin spines and without a notable head are called dendritic 
filopodia, and are more numerous than spines in developing neurons. The dendritic 
filopodia are transient and highly motile protrusions that can develop synaptic input into 
mature spines, thus initiating synaptogenesis72,79. 
Usually, an incoming stimulus provokes reversible modification of spine plasticity, with 
related arrangement of shape, length and functionality; in some pathological instance the 
stimulus can persist, determining a complete loss of function followed by a total spine 
retraction, with related biochemical and structure loss. The irreversible perturbation of 
the synaptic function is known as synaptopathy.  
 
2.1. Synaptopathology  
Many neurodevelopment disorders, such as RTT, Angelman or Down syndrome are 
characterized by abnormal density and morphology of dendritic spines, synapses loss and 
aberrant synaptic signalling and plasticity80, hallmarks of synaptic pathology. 
Synaptopathology, defined as the dysfunction of synapses, can be generated by a gene 
mutation of synaptic proteins such as ion channel, neurotransmitter receptor, or protein 
involved in neurotransmitter release. It can also arise as a result of an autoimmune 
response, in which antibody bind a synaptic protein.  
Synaptic dysfunction is one of the first signs that occurs in neurodegenerative pathology. 
Morphological changes correlate often with alteration of functions in this area and affect 
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communication among neurons. A complete loss of synaptic function is strictly related to 
cognitive deficits, hallmarks of brain disorders.  
Many studies have shown that the dynamic process leading to spine loss is associated 
with a decrease in glutamate receptors 81–84 and normally occurs in 3 steps. In fact, spines 
have a stable conformation as long as a stimulus, such as Aβ oligomers, leads to the first 
step of synaptic dysfunction, characterized by internalization or desensitization of NMDA 
and AMPA receptors and by a slight reduction of scaffold protein such as PSD-95 protein. 
Moreover, direct postsynaptic activation of α7 nicotinic acetylcholine receptor (α7-
nAChR) was proposed and then, the activation of extrasynaptic NMDA receptors,{Merging 
Citations} particularly NR2B-mediated NMDA currents, was shown.  Numerous intracellular 
signalling pathways like calcineurin/STEP/cofilin, p38 MAPK, and GSK-3β could be 
activated. this reversible step is followed by, a major decrease of PSD-95 occurs inducing 
an atrophy of the post-synaptic element that generate synaptic loss and eventually 
neuronal death85,86 
Figure 7- Pathological mechanism of synaptic dysfunction.  The post-synaptic region show a specialized 
cell membrane structure called the postsynaptic density region (PSD). This zone contains many scaffolding, 
like PSD-95 and Shank3, which plays an important role in AMPA (red channels) and NMDA (green 
channel) receptors localization. Slight perturbations of the spine architecture lead to spine dysfunction and 
subsequently loss.  
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2.2. Role of the major scaffold proteins: PSD95 and SHANK3 
The efficient regulation of synaptic signal transduction of the excitatory synapses is 
provided and supported by the postsynaptic density (PSD), that is an electron-dense 
structure attached to the cytoplasmic surface87,88. The PSD consists of hundreds of 
proteins with a molecular architecture not yet fully understood. A well characterized 
family of protein belong to the MAGUK family (membrane-associated guanylate kinase). 
This protein network plays a role in the regulation of the short- and long-term changes 
that affect the synaptic transmission during the lifetime of a mature neuronal circuit, in 
synaptic plasticity helping to regulate scaffold proteins located in the post-synaptic 
density region (PSD)89.  
Among MAGUKs, the PSD95 is the most abundant scaffold protein of the excitatory 
postsynaptic density90 and is involved in the regulation of AMPA receptors upon 
induction of LTP91,92, which presumably underlies its essential role in learning and 
memory. Moreover, PSD-95 have shown an important influence in localization and 
organization of receptors, ion channels, kinases, phosphatases and signalling 
molecules93,94.  PSD-95 structure and its important interactions are shown in the figure 8. 
The protein consists of three PDZ domains followed by a src homology 3 (SH3) domain 
and a guanylate kinase-like (GK) domain95. PDZ domains 1 and 2 of PSD-95 bind to 
various membrane proteins including the NMDA receptor subunits96, whereas the third 
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PDZ domain of PSD-95 (PDZ3) preferentially binds the C termini of a different set of 
proteins, including, for example, the synaptic protein CRIPT97. 
Figure 8- PSD95 structure, location and interaction. PSD95 protein belongs to the MAGUK family and 
thanks to its specific domains (PDZ, SH3 and GK) allows interaction with different kind of proteins involved 
in modulation of cellular pathway in the dendritic spines. 
 
PSD-95 is thought to determine the size and strength of synapses and to be involved in 
spine stability. Many studies reported that modifications of the protein, as well as 
phosphorylation of PSD-95, are related to a remodelling of proteins and receptors of 
dendritic spines and molecules were re-located, leading to a disruption of spine 
morphology. 
Shank family (Shank1, Shank2, Shank3) is made up of scaffold proteins interacting with 
a variety of cytoplasmic and membrane protein98, for example are the most abundant 
binding partners of Homer protein in the PSD90. Shank contains an amino-terminal 
ankyrin repeat domain, an SH3 (Src homology 3) domain, a PDZ (PSD-95/Discs 
large/zona occludens-1) domain, a long proline rich sequence containing binding sites for 
Homer and cortactin, and a carboxy-terminal SAM (Sterile alpha motif) domain99,100.  
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In a similar way to PSD95, through these domains, Shank directly interacts with AMPA 
and NMDA receptors101 and many other signalling and scaffolding molecules in the PSD 
region. De novo mutation of Shank3 was found in a patience with a RTT-syndrome like 
phenotype102. Overexpression of Shank in neurons results in enlargement of dendritic 
spines, and the effect is significantly enhanced by co-expression of the long form of 
Homer 103. 
Figure 9- Structure and function of SHANK3 scaffold protein. 
 
2.3. Rett syndrome as an example of synaptic dysfunction 
RTT patients are affected by a dendritic spine dysgenesis which includes not only lower 
spine density, but also atypical morphology, resulting in a decreased proportion of 
mushroom spine in cortex and hippocampus104–106. The brain of RTT patience is 
characterized by typical hallmarks, including reduced neuronal size and increased 
neuronal density in several brain regions107,108, as well as reduced dendritic arborisation104 
and spine dysmorphogenesis105,106,109. Similarly, mouse models of RTT are widely used 
and recapitulate many of the behavioural and anatomical abnormalities associated with 
the human disorder 110,111 the alteration in density30,112–114, size and shape 115,116 ; moreover 
they are affected by an important impairments in both LTP and LTD32,117,118. The so-
called spine dysgenesis phenotype119 is recapitulated not only by MECP2-null mice but 
also by mice with only a region-specific deletion of MECP255,57. Interestingly, pyramidal 
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neurons of the hippocampus of Mecp2 KO have fewer dendritic spines only before 
postnatal day 15, suggesting that MeCP2 is necessary for dendritic spine formation during 
early postnatal development, but a compensatory mechanism takes place after this period 
in Mecp2 KOs62,106. 
The same dendritic spine phenotype is delayed in female heterozygous mice, and it 
seemed more severe in Mecp2-expressing neurons than in Mecp2-lacking neurons, 
suggesting both cell autonomous and non-cell autonomous consequences 
of Mecp2 deletion120. In addition to similar lower spine densities, the intensity of 
immunolabeling for PSD-95 was lower in layer V pyramidal neurons of motor cortex of 
Jaenisch Mecp2 mutant mice30. 
Figure 10- Healthy and pathologic RTT dendritic spine. 
 
Synaptic dysfunction seems to be localized in particular region of the brain. In RTT 
patients, cortical networks are weakened and hypo-active. Dendritic spine density is 
lower in pyramidal neurons of layers V-VI of motor cortex from male hemizygous and 
female heterozygous Bird Mecp2 knockout mice120. 
Mouse models showed a significant volumetric reductions of cortex and cerebellum, and 
decreased ratios of the thickness of motor cortex to cerebrum and corpus callosum to 
cerebrum121. While cortical lamination was normal, the thickness of somatosensory and 
motor cortices was significantly reduced in comparison to wt males116,121,122. Cerebellum 
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appear to be normal, but analysing cerebellar vermian lobules or the corpus callosum of 
RTT pateints, they showed significantly decrement. Cerebellar atrophy may contribute to 
the deterioration of the motor system seen in older patients with Rett syndrome123 
Pyramidal neurons in the cortex115 and hippocampal CA3 region, as well as granule cells 
of the dentate gyrus show reduced dendritic complexity36 and have lower spine densities 
compared to wildtype controls116. Furthermore, pyramidal neurons in CA1 region of the 
hippocampus from Bird Mecp2 knockout mice also show lower spine densities, in addition 
to dendritic swelling, reduced diameter of dendritic spine heads and elongation of their 
necks120. Intriguingly, this study described significant different consequences between a 
deletion55 and expression of a truncated Mecp2 protein57.  
Moreover, degeneration and loss of spinal ganglion nerve cells, in addition to gliosis of 
both the white and grey matter of the spinal cord, were evident. The number of motor 
neurons appeared to be reduced and axonal changes suggestive of degeneration were 
observed in both the ascending and descending tracts124. 
. 
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3. SYNAPTOPATHY AND MAPKS  
Synaptic plasticity is regulated by different intracellular signalling pathways. Among 
them, mitogen-activated protein kinases (MAPKs) have shown to have a role in 
controlling neuronal synaptic function phosphorylating many targets at the spine level. 
In mammals, three main classes of MAPKs have been characterized: JNK, p38 and 
extracellular signal-regulated kinase (ERK)125. It is assumed that ERK1/2 mediates 
preferentially proliferation and differentiation, being activated by growth factors, while 
p38 and JNK respond to stress stimuli to induce mainly apoptosis. 
The molecular mechanisms underlying the synaptic adaptability to injury remain almost 
unclear, but there are increasing evidences of the involvement of mitogen-activated 
protein kinases (MAPKs). JNKs are a family of kinase protein, found to be involved in 
dendritic spine plasticity and stability. In our previous works, we showed that in 
neurodegenerative disease, such as Alzheimer’s disease, Aβ oligomers caused  a strong 
activation of the JNK pathway in the synaptic compartment, indicating a key role in this 
first neurodegenerative event. This activation occurs prior to the onset of the cognitive 
impairment126 and it is correlated with spine density reduction, decrement of postsynaptic 
markers (AMPAR and NMDAR subunits, PSD95 and drebrin) and activation of caspase-
3 in the postsynaptic compartment.  
To confirm the involvement of JNK in synaptic degeneration mechanisms induced by Aß 
oligomers, we used the specific cell permeable JNK inhibitor peptide, D-JNKI1. 
Treatment with D-JNKI1 reverted the synaptic degeneration, preventing the loss of 
dendritic spines and the reduction of AMPA-r and NMDA-r subunits, PSD95 and drebrin 
from the postsynaptic membrane127. Moreover, D-JNKI1 treatment was able to reduce 
excitatory synapses retraction, reverting their dysfunction, revealing that JNK is a key 
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signalling pathway in synaptic injury and that its specific inhibition offers an innovative 
therapeutic strategy to prevent spine degeneration126.  
Rett syndrome is a neurodevelopmental disorder different from AD, but in the same way 
is characterized by a strong synaptic dysfunction with an aberrant synaptic plasticity, so 
we investigated JNK activation and its role in this pathology. 
 
C-Jun N terminal kinase (JNK) 
JNK proteins are a family of evolutionarily conserved serine/threonine kinases. They 
have first been discovered in a c-Jun binding assay128 where JNKs were shown to bind 
the activation domain of c-Jun  128,129 and phosphorylate it at Ser63 and Ser73 residues 
located in the N-terminus130. In mammalian genomes three genes (JNK1, JNK2 and 
JNK3) encode a family of three JNK isoforms (Jnk1, Jnk2, and Jnk3 also termed SAPK-
γ, SAPK-α and SAPK-β, respectively) with a total of ten splice variants. Jnk1 and Jnk2 
are widely expressed in a variety of tissues, while expression of Jnk3 is mainly located 
into brain, heart and testis131,132. The structure of the different Jnk isoforms is essentially 
the same, since they share an 80% sequence identity. They all possess three relevant 
domains for JNK function, that are: the activation loop, the active site, and the peptide 
binding site.  
The activation loop or phosphorylation lip is the region containing the JNK regulatory 
phosphorylation. It is composed by a tripeptide, Thr-X-Tyr, where X is a proline, a 
glutamate and a glycine in the sequence of JNK, ERK and p38, respectively. The 
activation loop is adjacent to the active site.  
The active site is composed by a glycine-rich phosphate anchor loop with a role in the 
ATP binding. The adenine base of ATP is bound in the back of the domain interface and 
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forms non polar interactions with amino acids of the glycine loop132. The conserved 
Asp189 and Asp207 residues are thought to be essential for protein kinase activity.  
At least, the substrate binding site lies in the C-terminal domain and is formed by a loop 
contiguous with the phosphorylation lip. Changes in conformation in this region allow 
substrate binding to the active form of JNK, explaining how phosphorylation at the 
activation loop may play a role in the activation of JNK.  
A huge number of studies demonstrated that JNK has a central role in development and 
in many different diseases. In particular, JNK pathway is involved in pathogenesis of a 
great variety of CNS diseases, i.e. in cerebral ischemia133,134, in Parkinson disease (PD)135, 
in AD136, and recently in X-fragile syndrome137, very similar to RTT.  
 
3.2 Physiological and pathological functions of JNKs 
The JNK basal activity is higher in the brain than in other tissue where it is involved in 
both physiological than pathological processes. Concerning physiological functions, JNK 
has shown a role in regulation of homeostatic processes in development and in the adult 
brain138. During development, JNK is involved in regulation of neuronal death138, in 
modulation of microtubule dynamics139, in dendritic formation and elongation as well as 
in branching and sprouting140, in neuronal polarity and in axonogenesis89,141,142. The role 
of JNKs in the regulation of the neuronal cytoskeleton was initially supposed by their 
localization within cytoskeleton associated structures such as synapses, growth cones, 
and cell membranes in primary hippocampal neurons. This hypothesis was then 
confirmed by the observation that deletion of JNK1 induces progressive degeneration of 
long nerve fibres, substantial reduction of dendrite length as well as atrophy in dendritic 
spines143,144. Additionally, cytoplasmic JNK substrates such as doublecortin (DCX) and 
SCG10 are involved in promoting neurite extension and stability144. In the adult brain, 
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JNKs are important in various aspect of plasticity, learning and memory formation140, 
although their role is partially unexplored. Noteworthy, JNKs are implicated in membrane 
receptor mobility and in particular in AMPA receptor trafficking following changes in 
neuronal activity145,146. JNKs have shown an involvement in learning and cognitive 
processes, by the way, the exact molecular mechanisms by which contribute to learning 
processes are far from being understood. Nonetheless potential downstream candidates 
regulated by JNKs may be proteins like: synaptotagmin-4147, cytoskeletal proteins such 
as MAPs148, AMPA receptors 145,146 and transcription factors, including c-Jun, ATF-2, 
calcium/cAMP response element binding protein (CREB) and Elk-1132. Such substrates 
are good candidates in JNK mediated pathways during learning since they are involved 
in memory processes.  
Whereas, the importance of JNKs in pathological conditions lies on the fact that they are 
activated by a variety of stress signals, including UV irradiation149, pro-inflammatory 
cytokine, oxidative stress150,151, excitotoxicity 133,152, hypoxia and glucose 
deprivation153,154  as well as cerebral ischemia133 and have a well-established role in 
apoptosis, necrosis and autophagic cell death155–157. In fact deletion or inhibition of JNKs 
prevents neuronal programmed death 158, in particular, JNK3, and not JNK1 or JNK2, is 
required for the apoptosis of hippocampal neurons induced by glutamate receptor agonist 
kainic acid, clearly establishing that JNK3 is essential for mediating the apoptotic 
response of neurons to stress138. Finally JNK is a key player in Alzheimer disease as 
discussed before126,127,159. 
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Figure 11- JNK activation and function. As discussed previously, JNK is activated by many stimuli and is 
implicated in apoptosis, gene transcription, mRNA stability and in signalling in the post-synaptic region. 
Image taken by c-Jun N-terminal kinase-dependent mechanisms in respiratory disease of B. L. Bennett- 
European Respiratory Journal 2006 28: 651-661; DOI: 10.1183/09031936.06.00012106 
 
3.3 Regulation of JNK 
Analogous to other MAPKs, JNKs are activated by dual phosphorylation on Thr and Tyr 
residues within the Thr-Pro-Tyr motif in the phosphorylation lip. These phosphorylations 
are mediated by two MAP kinase kinase (MAPKK), which are in turn activated by 
multiple MAP kinase kinase kinase (MAPKKK)160. Two MAPKKs have been identified 
for JNKs: MKK4 and MKK7. While MKK7 is a specific activator of JNK and 
phosphorylates predominantly the Thr residue, MKK4 can also activate p38 and 
phosphorylates predominantly the Tyr residue131,161,162. This specificity suggests that JNK 
can be activated by MKK4 and MKK7 depending by some circumstances131. The fact that 
is sufficient a mono phosphorylation of JNK on Thr residues to increase JNK activity, 
indicated that MKK7 is important to trigger JNK activity whereas the additional 
phosphorylation of the Tyr by MKK4 ensures optimal JNK activation162.  
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MKK4 and MKK7 protein kinases are activated in turn by a dual phosphorylation of 
MAPKKKs. Several MAPKKKs have been reported to activate the JNK signalling 
pathway. These include members of the MEKK group (MEKK1-4), the mixed-lineage 
protein kinase group (MLK1, MLK2, MLK3, DLK, and LZK), the ASK group (ASK1-
2), TAK1, and TPL2131. Some of these MAPKKK can activate MAPKK without 
distinction, others bind specifically to one MAPKK. For instance, MLK3, MEKK1 and 
TAK1 can interact with both MKK7 and MKK4163–165, while MEKK4 specifically bind 
to MKK4166, and DLK to MKK7167.The specific transmission of signals from the 
upstream kinase to the MAPKs is ensured by interaction between the components of the 
cascade either directly or via scaffold proteins149,168. Both mechanisms may operate in 
parallel to allow differential responses of the same MAPK signalling pathway to different 
stimuli169. Scaffold proteins, such as JIP1, interact with several enzymes of the JNK 
cascade, creating multi-enzyme complexes131. These multimerized complexes organize 
the pathway and facilitate interactions with proteins, accelerating the activation cascade 
and localizing the signal in a specific cellular compartment or a restricted region of the 
cell131,170,171. 
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Figure 12- MAPK signalling pathway. On the left side it is a schematic representation of MAPK activation 
that occur thanks to successive phosphorylation, generated by a stimulus. On the central and on the right 
side are shown the pathway involving respectively, activation of p38 and JNK.  
 
C-Jun: the main JNK target 
Physiological and pathological stimuli induce activation of the transcription factor c-Jun, 
involved in neurodegenerative functions172. Together with Fos, ATF, and Maf 
subfamilies, c-Jun is the major component of the AP-1 complex, involved in cellular 
processes regulation, including differentiation, proliferation, and apoptosis173.The variety 
of dimeric complexes and the dual roles of AP-1 as a transcriptional activator and 
repressor of genes may explain how c-Jun regulates so many different, and sometimes 
opposing, cellular processes174.  
The c-Jun promoter region contains several regulatory elements, including TRE 
(tetradecanoyl phorbol acetate response element)175,176, that binds dimers of c-Jun and 
ATF factors regulating its own expression.  
The transcriptional activities of c-Jun is regulated upon phosphorylation by various 
protein kinases, including the mitogen-activated protein kinases (MAPK), mainly by JNK 
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with a rapid, large, and transient stimulation177,178.In fact, c-Jun can bind DNA target 
sequence motifs after a double phosphorylation by the Jun N-terminal kinases (JNKs) at 
serines 63 and 73179. This modification increase Jun’s activity (AP-1 activity) and gene 
target transcription in stress-induced apoptosis and cellular proliferation180. Basal 
expression is detected in various compartments including dentate gyrus, motoneurons, 
peripheral neurons and nuclei of the autonomic nervous system following excitotoxicity 
stimulation and destruction of the neuron-target-axis including withdrawal of trophic 
molecules. 
The c-Jun/JNK-axis is involved in neuronal plasticity and in memory formation: taken 
together, they participate in cytoskeletal alterations, in neuronal differentiation, in neurite 
extension and maturation of neural cells, and finally, initiate long-lasting genetic 
alterations by activation of TFs such as c-Jun, Jun-D or ATF-2132,181. Moreover, c-Jun 
appears to be essential for hippocampus-dependent learning behaviour and amygdala-
dependent fear-conditioning responses. However, c-Jun proteins also regulate 
degeneration, apoptosis in the CNS and upregulation of harmful programs in non-
neuronal cells (e.g. microglia and astrocytes) with release of neurodegenerative 
molecules.  
The apoptosis-realizing target genes of c-Jun/AP-1 are not well defined. Fas ligand182,183, 
TNFa184, cyclin D1185,186, p53187 may be c-Jun effectors, even if they are independently 
regulated by c-Jun/JNK or are not involved in neuronal apoptosis 188,189.  
Beyond direct transcriptional activation of endogenous neuronal killer proteins as it is 
likely for the kainic-acid induced hippocampal180,190, pro-degenerative effects of c-Jun 
can be exerted by transcription of genes which enhance the pathological stress. Inhibition 
of c-Jun/JNK axis may be useful to contrast neurodegeneration. 
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4. CELL PERMEABLE PEPTIDES 
Cell penetrating peptide (CPP) are short peptides that facilitate cellular intake/uptake of 
various molecular equipment (from nano-size particles to small chemical molecules and 
large fragments of DNA). The typical structure of a CPP is composed of a CARGO 
peptide linked to an effector-peptide. The cargo is associated with the peptides either 
through chemical linkage via covalent bonds or through non-covalent interactions.  
Figure 13-  Schematic representation of the CPP compose of a CARGO sequence 
(tat in green) and an active effector (in white). 
 
The cargo is transported into cells usually by unfolding the bilayer of the biological 
membrane. The cellular up-take is possible thanks to positively charged amino acids, such 
as lysine or arginine. The CPPs may be synthetically designed and allow a non-invasive 
import of different cargos. This technology shows numerous advantages that include: 
high and rapid output, relatively low costs for synthesis, versatility (few scaffold cores 
can be used to generate several compounds able to act at different levels from kinases 
inhibitors to secretase-like molecules), stability (when synthesized in D-amino acids), low 
catabolism, and low toxicity. Last but not least CPPs can be active in a range of nanomolar 
concentrations170. Consequently, CPPs are attractive drug delivery tools being capable of 
targeting intracellular signalling pathways as well as interfering with intracellular protein-
protein complexes to rebalance a perturbed cellular function170.  
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The cell permeable inhibitor of JNK, D-JNKI1191, produces an allosteric modulation of 
JNK by blocking the access of the kinase to some of its targets, preventing protein-protein 
interactions, without interfering with its activation. The JIP-1 scaffold protein and c-Jun, 
the main target of JNK, share a similar JNK binding domain (JBD). However, JNK 
binding affinity to JIP-1 is about 100-fold higher than to c-Jun, for this reason the inhibitor 
peptide is able to block the access of JNK to its preferential substrate. D-JNKI1 peptide 
has been engineered by linking the 20 amino acids of JIP1 to 10 amino acids of the TAT-
sequence of the human immunodeficient virus (HIV)191. Between the TAT and the JBD20 
sequence, two proline-residues were inserted as spacer to allow for maximal flexibility. 
Thanks to those polycationic residues, D-JNKI1 can cross biological membranes via an 
energy-independent cellular process. Moreover, D-JNKI1 sequence has been synthesised 
with D-aa and in a retro-inverse form. These modifications lead to a significant increase 
of peptide stability, since D-aa are not recognized by endogenous proteases, and to a 
reduction in the immunogenic response.   
The inhibitory action of D-JNKI1 peptide is fundamentally different from that of classical 
small chemical inhibitors133,191,192. D-JNKI1 does not inhibit JNK enzymatic activity, but 
selectively blocks access to many of its substrates by a competitive mechanism192,193.  
To determine the specificity of the peptide in blocking JNK action, the effects of the 
peptide on the activity of 40 different kinases towards their respective substrates in a cell 
free system was characterized193,194. D-JNKI1 did not interfere with the activities of other 
kinases, proving its exceptional selectivity for JNK, if compared to chemical inhibitors. 
D-JNKI1 peptide completely inhibits excitotoxicity in primary culture and strongly 
prevents neuronal loss against two different models, transient and permanent, of middle 
cerebral artery occlusion (MCAo)133,195. Additionally, other authors demonstrated 
powerful protection by D-JNKI1 in different models of CNS injury: D-JNKI1 protects 
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against toxic drug and acoustic trauma induced auditory hair cell death196 as well as 
against retinal ganglion cells death following optic nerve crush197. Moreover, we found 
that inhibition of JNK pathway was usefully in rescuing cognitive and synaptic deficit in 
AD159 and in rescuing function and locomotor ability after spinal cord injury198. This cell 
permeable peptide inhibitor thus offers interesting possibilities for therapeutic 
application.  
 
4.1. JNK inhibitors 
Because of JNK role in a variety of pathologies, several research laboratories have 
proposed JNK inhibitors (Figure 14) to find effective drugs for their treatment. 
Figure 14- JNK inhibitors and their targets.CEP-1347 inhibits the MLK 
group of MAPKKK, while SP600125 and D-JNKI1 block JNK.   
 
Inhibitors could be divided mainly in two classes: chemical compounds and cell 
permeable peptides (CPPs) inhibitors. Chemical compounds are small organic 
competitive inhibitors of the ATP-binding site of the kinase. At contrary, cell permeable 
peptide (CPPs) are short and positive peptides composed of lysine or arginine residues  
(20 to about 50 amino acids) which can cross the cellular plasma membrane199 delivering 
biological active proteins to all tissues, including the brain. Among all, two chemical 
inhibitor compounds, CEP-1347 and SP600125, have been developed and tested. 
However, the published information on their efficacy in clinical trials remains limited. 
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CEP-1347 is a semi-synthetic inhibitor of the upstream component of the JNK pathway, 
blocking MLK group of MAPKKK as shown in Figure 16 200. CEP-1347 promotes 
survival of a variety of primary neurons in cell culture after either trophic factor 
withdrawal, DNA damage, or oxidative stress200,201. Moreover, in vivo it demonstrated to 
prevent neuronal cell death in models of AD, PD and cochlear hair cell death196. 
SP600125, developed by Celgene, is an ATP competitive inhibitor of JNK which inhibits 
all three JNK isoforms as well as c-Jun phosphorylation in a dose-dependent manner. 
However, it is not selective for JNK, since it also inhibits MKK4 and MKK7 activity as 
well as other MAPKs, such as ERK and p38, at higher doses202.  
In vivo, this compound protects dopaminergic neurons in the MPTP model of PD 196 and 
it was used to attenuate apoptosis in a model of AD neurotoxicity 203. 
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5. AIM OF THE WORK 
Rett is a rare neurodevelopmental disorder that affects usually female in the first decade 
of life. Children affected by this pathology loss gradually their abilities to speech, to walk 
and develop autism features, epilepsy and breathing problems that get worst with time. 
Since RTT a genetic disease, today there is no cure for this disease, neither there are 
effective pharmacological treatments to reduce the locomotor and cognitive damage 
associated with this pathology.  
c-Jun N-terminal protein kinase (JNK), is a stress-activated protein kinase, which plays 
an important role on synaptic functionality. It showed an involvement in 
synaptopathology related with Alzheimer’s disease, spinal cord injury and ischemic 
stroke; its inhibitions revealed a real rescue of synaptic receptors levels, accompanied by 
an amelioration of cognitive and locomotor deficits. With those evidences in hand, we 
started to be interested in JNK’s role in RTT. Its inhibition may represent an innovative 
strategy to tackle the syndrome. The main aim of this work was to characterize the JNK’s 
role in the syndrome, analysing the D-JNKI1 effect (a cell permeable peptide JNK 
inhibitor) by behavioural, biochemical, and immunohistochemical studies in a mouse 
model of RTT. We choose a model with the most aggressive phenotype in order to 
evaluate the potentiality in preventing symptoms. To achieve this purpose, we performed: 
* MeCP2 mouse model characterization; 
* D-JNKI1 treatment evaluation on behaviour of MeCP2 mice; 
* Biochemical evaluation of D-JNKI1 treatment on MeCP2 mice; 
* Immunohistochemical evaluation of D-JNKI1 treatment on MeCP2 mice; 
* Morphological evaluation of D-JNKI1 treatment on MeCP2 mice; 
* D-JNKI1 treatment evaluation on neuroinflammation associated to MECP2 mice. 
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Furthermore, to evaluate the effectiveness of D-JNKI treatment, and to translate it to 
human patients, we decided to test the peptide action in IPSCs derived from RTT patients.  
We strongly believe that such approach will allow us to create a translational model from 
animal to human aimed to demonstrate the beneficial effect of D-JNKI1. D-JNKI1 
treatment trying to translate from mouse to human model, evaluating its effect on IPSCs 
obtained from RTT patients (on going experiments). 
This work will evaluate efficiency and safety of our approach and if successful, it provides 
a proof of principle for a novel therapeutic RTT modality that will be further advanced 
for clinical development. Last but not least, D-JNKI1 peptide is already in phase III 
clinical trials, consequently reducing the timing of reaching the actual availability of the 
peptide. 
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6. MATERIALS AND METHODS 
6.1 Animal breeding 
All animals used in experimental procedures are housed in according with European 
procedures. Mice were purchased from Jackson Laboratory, and bred at IRCCS Mario 
Negri Institute of Pharmacological Research in a specific pathogen free (SPF) facility 
with a regular 12:12 h light/dark cycle (lights 07:00 a.m- 7:00 p.m.), at a constant room 
temperature of 22 ± 2°C, and relative humidity approximately 55 ± 10%. Animals were 
housed (3-4 per group) in standard mouse cages, all with hard wood shavings as bedding 
material, ad libitum food (Global Diet 2018S, Harlan Italy) and water. 
For our experiments, as largely discussed in the introduction, we used Mecp2 tm1.1Bird 
animals61, that present a deletion in exon 3 and 4 and consequentially no detectable 
MeCP2 protein level in homozygous (male mice) indicated as Mecp2-/y and 50% of 
protein in heterozygous mice (female) Mecp2+/-. Moreover, females are affected by X-
chromosome random inactivation and presents a very variable phenotype, depending 
from cells lacking the protein. The 21th day after birth, the animals were weaned and 
genotyped by PCR to identify the different genetic mutation. 
Male mice, used for treatment, were weaned at the 19-20th days; the day after they were 
intraperitoneally injected with a D-JNKI1 (AURIS MEDICAL) 2mM solution (22mg/kg) 
at the 21st day and at the 42nd day. Mice were weighted before and after treatment and 
every time they were used for behavioural tests; when they reached 7 weeks of age, mice 
were sacrificed by decapitation and used for the biochemical, immunohistochemical and 
mRNA expression evaluations. 
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6.2 Polymerase chain reaction (PCR) for genotyping 
To obtain mutated mice, we mated two heterozygous females with a wild-type male. We 
analised DNA from puppies’ ears or tails pieces. DNA was extracted with a solution of 
NaOH (Sigma Aldrich) 50 mM for 1 hour at 99°C. After complete digestion, samples 
were adjusted of TRIS-HCl solution 80 mM and were stored at 4°C till use. DNA 
amplification was conducted with a commercial kit buy from Promega (GoTaq® G2 Flexi 
DNA Polymerase) and primers (Sigma-Aldrich) with the sequences reported on the 
Jackson Laboratories web site, which are: 
COMMON:   5’-AAA TTG GGT TAC ACC GCT GA-3’ 
MUTANT REVERSE:   5’-CCA CCT AGC CTG CCT GTA CT-3’ 
WILD TYPE REVERSE:   5’-CTG TAT CCT TGG GTC AAG CTG-3’ 
Amplification cycles were performed with the BioRad S1000TM thermal-cycler, 
following the instruction reported by Jackson Laboratory who provided us mice (94°C 
for 2min; 10 cycles at 94°C for 20 sec, 65°C for 15 sec, 68°C for 10 sec; then 28 cycles 
at 94°C for 15 sec, 50°C for 15 sec, 72°C for 10 sec; at the end 72°C for 2 min and 4°C). 
to visualize reaction product, we performed an electrophoretic run on agarose gel (1,5%) 
at 100V for almost 20 minutes. 
 
6.3 Body weight and survival  
Animals were monitored daily for well-being and welfare-related disease symptoms. 
Their body weights were recorded weekly. Body weight loss more than 15% in two 
consecutive weeks (15% + 15%) was considered the humanitarian end-point of the 
study and the animals were euthanized. The trial was stopped 7 weeks after starting the 
study because of higher mortality in the KO groups.  
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6.4 Behavioural tests 
6.4.1 Rotarod 
Rotarod test was performed using the accelerating Rotarod apparatus (Ugo Basile 7650 
model, in fig.15)204. The apparatus has a rotating bar subdivided in 5 slots to test in the 
same time 5 animals.  Once the animals were positioned on the bar, time was started and 
the rod was accelerated at a constant rate of 0.3 rpm/s from 3 rpm to 30 rpm for a 
maximum of 5 min. The latency to fall was scored in seconds at which the animal fell 
from the bar.  
                                    
Figure 15- Rotarod apparatus. One mice in one slot could be individually evaluated. When mice falls 
down, the Rotarod registered time of latency automatically. 
  
Motor coordination was tested by considering this latency time in every trials that mice 
performed205,206. Test was performed once a week, starting from the 3rd week to 7th week 
of life; tree trials were given to each animal and all times performed were recorded. we 
used ten animals for each experimental group. 
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6.4.2 Open field (OF) test 
The OF test is used to examine general locomotive behaviour, as well as exploration and 
consequent level of anxiety, by exposing mice to a novel, open space207,208. We used a 
grey Perspex OF box (40 × 40 × 40 cm) with the floor divided into 25 (8 × 8 cm) squares 
(Fig. 17). Mice were placed in the centre of the floor defined as a ‘starting point’ and their 
behaviour was video-recorded.  
                                   
Figure 16- Open field apparatus 
 
The mice behaviour was analysed for 5 min to measures spontaneous locomotor activity, 
exploratory activity and state of anxiety. At this purpose, we considered as parameters: 
* time of locomotion divided into the number of internal (the 9 central squares) and 
external (the 16 peripheral squares) squares crossed,  
* time spent in the central and outer area of the open field,  
* mean of velocity gain from mice in the arena; 
* time in which mice is immobile for more than 5% of pixel movement 
* number and duration of rearing (standing on the hind paws),  
* number and duration of self-grooming (rubbing the body with paws or mouth and 
rubbing the head with paws)209  
For the OF at 7 weeks of age we used ten animals for each experimental group. 
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6.5 Subcellular fractionation (TIF) 
After performing behavioural tests at 7 weeks, mice were sacrificed by decapitation and 
used for biochemical evaluations. After dissecting, subcellular fractionation was 
performed as reported in the literature with minor modifications both for cortex and 
cerebellum from hemizygous mice210. Briefly, tissue was homogenized with a glass-glass 
potter in 0.32 M ice-cold sucrose buffer containing the following (in mM) concentrations: 
1 HEPES, 1 MgCl2, 1 EDTA, 1 NaHCO3, and 0.1 PMSF, at pH 7.4, in the presence of a 
complete set of protease inhibitors (Complete; Roche Diagnostics, Basel, Switzerland) 
and phosphatases inhibitors (Sigma, St. Louis, MO). A part of this homogenate was stored 
at -80°C to be used as whole extract. Samples were centrifuged at 1000 × g for 10 min. 
The resulting supernatant (S1) was centrifuged at 3000 × g for 15 min to obtain a crude 
membrane fraction (P2 fraction). The pellet was dissolved in buffer containing 75 mM 
KCl, 1 mM HEPES and 1% Triton X-100 plus protease and phosphatases inhibitors and 
ultracentrifuged at 47,000 × rpm for 1 h. The supernatant was stored and referred to as 
TSF, triton soluble fraction (S4). The final pellet (P4) referred to as TIF, triton insoluble 
fraction that was resuspended with sonication (BANDELIN sonicator, 20 of power, 5 
cycles, 1 minutes each) in a 20 mM HEPES solution with a complete set of protease and 
phosphatases inhibitors and stored at − 80 °C until been used for further investigation. 
 
6.6 Western blot 
Protein concentrations were quantified using the Bradford Assay (Bio-Rad Protein Assay 
500-0006, Munchen, Germany). 10 μg of TIF (triton insoluble fraction) extracted proteins 
or 20 μg of total extract were separated by 10% SDS polyacrylamide gel electrophoresis. 
PVDF membranes were blocked in 5% no fat milk in Tris-buffered saline solution 0.1% 
Tween20 for 1 h at room temperature. Primary antibodies were diluted in the same buffer 
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(incubation overnight, 4 °C) using: anti NR2A and anti NR2B (1:2000, a kind gift of 
Alomone Lab), anti GluA1 (1:1000, Millipore), anti GluA2 (1:1000, Millipore), anti 
PSD-95 (1:2000, Cayman), anti Drebrin (1:1000, Enzo), GFAP (1:5000, Millipore), anti 
P-c-Jun (1:1000 cell signalling), anti c-Jun (1:1000 cell signalling), anti IBA-1 (1:1000 
WAKO). Anti.Actin (1:5000, Millipore) was used as housekeeping protein and at least 
six independent experiments were performed. Blots were developed using horseradish 
peroxidase-conjugated secondary antibodies (anti-Rabbit and anti-Mouse, as reported by 
datasheets from Santa Cruz Biotechnology) and the ECL chemiluminescence system 
(Promega). Western blots bands were quantified by densitometry using ImageJ software. 
 
6.7 Analysis of gene expression  
RNA was extracted from cerebellum of mice at 7th weeks of age. All samples were 
suspended in TRIzol reagent (Invitrogen, Milan, Italy), and RNA was isolated according 
to the manufacturer’s instructions. One microgram of RNA was used for cDNA 
preparation with Moloney murine leukemia virus reverse transcriptase (Promega, Milan, 
Italy), as previously described7. Control reactions without the addition of the enzyme 
were performed for each sample. A 1:4 cDNA dilution was amplified using SYBR green 
chemistry. The PCR was carried out in triplicate or duplicate on a 96-well plate using 
GoTaq®qPCR Master Mix technology (Promega) according to the manufacturer’s 
protocol using a 7900HT fast real time PCR system (Applied Biosystems, Life 
Technologies) with the following thermal profile: 2 min at 95 °C; 40 cycles, 15 s at 95 °C, 
1 min at 60 °C. Gene expression of target genes was assessed for Gfap (Gfap FW: 5’- 
AGGGCGAAGAAAACCGCAT-3’;Gfap REV: 5’-GGTGAGCCTGTATTGGGACA-
3’), Shank3 (Shank3 FW: 5’-CGGAGAAGAAAAGGGGAGAAGTT-3’; Shank3 REV: 
5’-CAATGTCCGGCCTCAGTGTC-3’), Iba-1 (Iba1 FW: 5’-
49 
 
ACCCAGCGGACAGACTGCCA-3’; Iba 1 REV: 5’-
TTTCCTCCCTGCAAATCCCTGCT-3’), C1qa (C1qa FW: 5’-
GACCACGGAGGCAGGGACAC-3’, C1qa REV: 5’- 
CTTCCCGTTGGGTGCTCGGC-3’). Data were analysed using the 
2−ΔΔCt method59 using 36b4 as the housekeeping gene (forward primer, 5′-
GGCGACCTGGAAGTCCAACT-3′; reverse primer, 5′-
CCATCAGCACCACGGCCTTC-3′). 
 
6.8 Immunohistochemistry 
Mice were deeply anesthetized with ketamine (100 mg/kg intraperitoneally, i.p.) and 
xylazine (10 mg/kg i.p.), and perfused through the ascending aorta with 50 mM cold 
phosphate-buffered saline (PBS, pH 7.4) followed by chilled 4% PAF in PBS. The brains 
were post-fixed at 4 °C overnight, and then transferred to 30% sucrose in PBS 0,01 M at 
4 °C for enough 24 h. Then, the brains were immersed in − 50 °C isopentane for 3 min 
and stored at − 80 °C until assayed. 
Serial coronal sections (20 μm) were cut from 0 to − 6.6 mm from bregma and were 
collected in 100 mM PBS. We prepared 6 series of 4 sections that were stained for GFAP 
(1:300, Millipore), CD11B (1:500, not-commercial, a kind gift of Veglianese’s group), 
NeuN (1:500, chemical MAB IgG1) and for P-c-Jun (1:50, cell signalling). 
Coronal cryosections (15 µm; Leica CM3050 S) from the total hemisphere were stored at 
−20°C. All sections were post–fixed with 4% formaldehyde (PFA) for 5 minutes, 
pretreated with 80% formic acid for 2 minutes and 2% H2O2 for 7 minutes. After washing 
with 10 mM phosphate buffered saline (PBS), pre - incubation solution (10% normal goat 
serum (NGS), 1% bovine serum albumin (BSA), 0.5% Triton X-100 in 10 mM PBS) was 
applied to the sections for 30 minutes at room temperature. Afterwards, the sections were 
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incubated with specific polyclonal primary antibody (Millipore) diluted following 
manufacter’s instructions in primary antibody solution (3% NGS, 1% BSA, 0.5% Triton 
X-100 in 10 mM PBS) at 4°C overnight. The antisera were generated and evaluated for 
specificity as described in datasheet. After washing steps, the sections were incubated for 
1 hour with a biotinylated secondary antibody (BA-1000, Vector Laboratories, CA, USA) 
diluted at 1∶300 in 3% NGS, 1% BSA, 0.5% Triton X-100 in 10 mM PBS, washed in 10 
mM PBS, and afterwards, incubated 1 hour at room temperature with streptavidin-
biotinylated horseradish peroxidase complex diluted at 1∶100 in 0.5% Triton X-100 in 10 
mM PBS. After washing with 10 mM PBS, all sections were incubated with 3,3′-
diaminobenzidine tetrahydrochloride (Sigma, MO, USA) for 5 minutes, before 0.1% 
H2O2 was added to 10 ml DAB solution and applied on the sections until proper labelling 
was achieved (3 minutes). The sections were briefly rinsed in water, mounted and stored 
at room temperature. 
 
6.9 IPSCs from Rett patients 
Fibroblasts were isolated from skin RTT patients and controls and cultured according to 
standard protocols were used for reprogramming following the procedure by Takahashi 
et al. (2007). Briefly, the IPSc were first re-programmed and then differentiated in 
neurons for 60 days. The neuronal-IPSc will be first analysed in order to identify dendritic 
spine and subsequently JNK activation will be measured as P-c-jun/jun ratio in neuronal-
IPSc of Rett patients versus control. 
Finally, neuronal-IPS cells were treated with D-JNKI 2 µM and 4 µM to value the effect 
of peptide on the synaptophaty associated to RTT syndrome. We lysed cell cultures in 
0.32 M ice-cold sucrose buffer containing the following (in mM) concentrations: 1 
HEPES, 1 MgCl2, 1 EDTA, 1 NaHCO3, and 0.1 PMSF, at pH 7.4, in the presence of a 
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complete set of protease inhibitors (Complete; Roche Diagnostics, Basel, Switzerland) 
and phosphatases inhibitors (Sigma, St. Louis, MO), the same used for mouse tissues. 
 
6.10 LDH assay 
Ldh assay is a test to evaluate level of the enzyme lactate dehydrogenase released by 
death cells in their medium culture. Medium was collected from cells before and after D-
JNKI1 treatment and stored at -20°C. We followed instruction reported by the 
commercial test (PROMEGA, ldh assay) and read the adsorbance at 495 nm with TECAN 
spectrophotometer. 
 
6.11 Statistical analysis 
Statistical analysis was done using Graph Pad Prism 6 program. Two groups data were 
analysed using unpaired t-Test, whereas when we have four conditions we used the two-
way ANOVA, followed by Bonferroni’s post hoc test.  All data were expressed as mean 
± SEM with statistical significance given at P< 0.05.  
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7. RESULTS 
7.1 Characterization of MeCP2 mouse model 
Rett syndrome (RTT) is caused by mutations of the MECP2 gene, which encodes for a 
transcriptional regulator with many functions carried out mainly in the brain. The disease 
is characterized by an onset not easily diagnosed, and highly variable phenotype. The 
high variability makes difficult to replicate motor and cognitive deficits of patients in a 
unique animal model. Among Rett mouse models, we used the MeCP2 Bird tm1.1 mouse 
model that replicates especially locomotives deficit and, to a lesser extent, cognitive 
ones55. 
The mice MeCP2tm1.1Bird, as amply described in the literature, have a deletion at the 
level of exons 3 and 4 of the MECP2 gene on chromosome X. Mutated male mice, defined 
knock-out (KO) or Mecp2 -/y, are hemizygous for the mutation and do not present 
detectable protein levels. Females are heterozygous for the mutation, defined Mecp2 +/-, 
are affected by mosaicism due to random inactivation of the X chromosome, a condition 
closer to human. Females Mecp2 +/- are fertile and have a high breeding index and to 
expand the colony two heterozygous females were crossed with a male wild type. During 
the breeding period, MeCP2 +/- female showed problems in nursing and caregiving to 
pups. To expand the mouse colony, the MeCP2 +/- were replaced post-partum with CD1 
mice nurses, to reduce the pups’ mortality and cannibalism episodes. Despite the nurse, 
many puppies were not able to feed themselves and to survive and we registered a death 
rate of 17%, as shown in Fig 17. 
In addition to the high mortality observed during the expansion of the colony, we found 
among survivor mice, a low percentage of hemizygous and heterozygous genotypes (23% 
for hemizygote MeCP2tm1.1 Bird -/y and 15% for heterozygotes MeCP2tm1.1 Bird +/-) 
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compared to the wild-type genotype, equal to 45%. Consequently, it was necessary time 
to expand the colony and to get Mecp2tm1.1bird -/y males used for our evaluation.  
 
Figure 17- Genotyping of MeCP2tm1.1 Bird mice. A) PCR analysis shows the different genetic background 
among wt (single line), MeCP2 +/- heterozygous mice (double line) and MeCP2 -/y hemizygous mice 
(single line down). B) Percentage of the different genetic background showed that 23% of total are MeCP2 
-/y (hemizygous, in blue) mice, 15% are MeCP2 +/- (heterozygous, in violet) mice, 44% are wild type mice 
(in white) and in grey are shown mice found dead in cage after birth corresponding to 17%. 
 
For our experiments, we chose male MeCP2 hemizygous mice model, because they show 
a rapid onset (at 3-4 weeks), see fig. 18A and a more aggressive pathological phenotype 
that bring them to have a high state of suffering and mortality around the 8th – 10th week 
of life as reported also by Guy in 2001. Despite heterozygous female are affected by 
mosaicism, they show a delayed onset (at 16-20 weeks, see fig 18B) and a milder 
phenotype.  
 
 
 
Figure 18- The differences between MeCP2 y/- and MeCP2 +/- mice concerning onset and progression of the 
pathology. Male hemizygous(A) shown a rapid onset, around the 3rd-4th week of life. The pathology is more severe and 
led to death in a very early stage of life, at maximum 10 weeks. Whereas, female (B) have symptom onset around the 
16th week of life, but pathology is not progressive. 
A B 
A B 
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Moreover, male present a more homogeneous genetic background which reduces the 
individual variability typical of  heterozygous female mice (affected by mosaicism), and 
this results in a simpler design of our study as well as interpretation of the results obtained. 
A summary of the major features of MeCP2 -/y mice is shown in table 2.  
Table 2. Summary of the general health, lifespan, behavioural and motor properties of MeCP2 tm1.1 Bird 
male mice. 
 
MeCP2 -/y mice are characterized by locomotor and cognitive impairments and a high 
rate of suffering with a dramatic decrease of body weight (15%) in MeCP2 -/y in the last 
stage of pathology. For these reasons, we decided to study the pathology in this mouse 
model from day 0 to 42 (corresponding to 7 weeks of age). 
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7.2 MeCP2 -/y metabolic profile characterization 
In order to characterize MeCP2 -/y animal model, we analysed the metabolic profile by 
evaluating the growth curves and the consumption of water and food during the entire 
experiment As shown in fig. 19, we found a highly significant effect of genotype (two-
way ANOVA, genotype effect #### p <0.0001) in males hemizygous Mecp2 -/y 
compared to wild type mice (wt), with a weight reduction of 60%.  
Figure 19 - Body weight of MeCP2 -/y or ko mice. Significant reduction of body weight in male MeCP2 
compared to wt mice analysed starting from 3rd week to the 7th week (n=10 for each group). Statistical 
analysis: two-way ANOVA genotype effect #### P<0,0001, post-hoc test Bonferroni's multiple 
comparisons test**** p>0.0001 MeCP2 -/y compared to wt mice. Data were shown as mean ± SEM. 
 
To understand if the decrement of body weight was related to a reduced consumption of 
water and food, we analysed these parameters since their weaning (3 weeks of age) until 
the end of the experiment (7 weeks of age). As shown in Fig. 20A, Mecp2 -/y mice 
showed no statistical significant differences in food consumption, meanwhile they shown 
a significant reduction in water consumption (two-way ANOVA, genotype effect #### p 
<0.0001; Fig. B) compared to wild type animals. 
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Figure 20 - Food and water consumption in MeCP2 -/y ko mice. A)No significant difference in food 
consumption of male MeCP2 -/y compared to wt mice in the time windows analysed (n=5 for each group). 
B) Significant reduction of water consumption in male MeCP2 -/y compared to wt mice in the time windows 
analysed (n=5 for each group). Statistical analysis: two-way ANOVA genotype effect #### P<0,0001, post-
hoc test Bonferroni's multiple comparisons test * P<0,05, *** P<0.001 **** P>0.0001 compared to wt 
mice. Data were shown as mean ± SEM. 
 
7.3 Evaluation of motor impairment in MeCP2 mice. 
A progressive deterioration of well-being was identified during the 7 weeks in MeCP2 -
/ytm1.1 Bird mice, related to an increasing reduction in body weight and food and water 
consumption. Then we decided to analyse the possible behavioural deficits associated 
with Rett syndrome. In order to evaluate the physical disabilities, similar to those of girls 
suffering from RTT, we administered Mecp2tm1.1Bird mice to specific tests widely used in 
science to assess locomotor deficits such as Rotarod and the Open Field Test (previously 
described in materials and methods). 
As shown in fig.21, results obtained with the Rotarod test (performed every 7 days from 
3rd to 7th week of life) showed a significant and progressive motor deficit in mice MeCP2 
-/y. In fact, the ability of MeCP2 -/y to perform on the rotating bar (measured with the 
latency time of each animal on the bar) was significantly lower (two-way ANOVA, 
genotype effect #### p<0.0001) when compared with wild type animals. Moreover, the 
deficit is progressive: the motor performance of MeCP2 males - /y at 3 weeks had a mean 
B A 
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of 177 seconds and, after a partial recovery until the 6th week of age with an average value 
of 229 seconds, there is a final reduction of the latency time equal to 164 seconds 
corresponding to the terminal stage of the disease. 
Figure 21-Evaluation of locomotor activity in MeCP2 mice by Rotarod test. Details of test are largely 
discussed in the text. We found a significant reduction of latency time in male MeCP2 -/y compared to wt 
mice in each point analysed (n=10 for each group). Statistical analysis: two-way ANOVA genotype effect 
#### P<0,0001, post-hoc Bonferroni's multiple comparisons test ** P<0,01, **** P<0.0001 compared to 
wt mice. Data were shown as mean ± SEM. 
  
To confirm and well-characterize locomotor deficits, we decided to test animals with the 
Open Field Test, which analyse not only related locomotor activity parameters (such as 
the total distance travelled, speed of movements and the time of immobility), but also 
exploratory related parameters (as the time spent in the central and peripheral arena, the 
number of crossings in these areas) and parameters related to an anxiety-like behaviour 
(as rearing and grooming). In fig.22A we can observe a significant reduction in the 
average distance travelled by MeCP2 -/y mice compared to wild type animals (two-way 
ANOVA, genotype effect #### p<0.0001). Consequently, MeCP2 -/y mice showed a 
reduced average in speed of movements (Fig. 22B; two-way ANOVA, genotype effect 
#### p <0.0001) and an increase of immobility (Fig. 22C; two-way ANOVA, genotype 
effect ### p <0.001) compared to wild type mice. Those evidences confirm the locomotor 
deficits and the progressive symptoms worsening in animals affected by RTT. In fact, the 
results obtained show a correlation between a reduced ability to move, a decrease speed 
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of movement and an increase state of immobility, highlighting how the animals MeCP2 
-/y spent progressively more time in a stage of immobility. 
  
 
 
 
 
 
 
Figure 22- Evaluation of locomotor activity in MeCP2 mice using Open field test. Analysing the distance 
moved (A), the velocity of crossing (B) in MeCP2 -/y and wt mice, we found a significant decrease in male 
MeCP2 -/y compared to wt mice in the time windows analysed. Valuating the immobile duration (C), we 
observed a significant increase in male MeCP2 -/y compared to wt mice (n=5 for each group). Significant 
relative to wt mice * p<0.05, ** p<0.001. Data were shown as mean ± SEM 
 
For whom it concerns parameters related to the exploration activities, we measured time 
in exploring the inner area and the outside area of Mecp2-/y mice, observing a tendency 
in spending more time in the outside zone and lesser in the inner zone (Fig. 22 A-C). We 
considered also the number of crossings from area to area, founding a significant 
reduction of this parameter in mice Mecp2-/y compared to wild type animals (Fig. 22 B-
D; two-way ANOVA, from centre to external zone genotype effect ## p <0.01, from 
external to centre zone genotype effect ### p <0.001). The results highlighted an 
exploratory locomotor deficits in line with the obtained data, because the animals Mecp2-
/y spend time in a stage of immobility, carrying only 8 crossings in 200 seconds in the 
outdoor area and 4 crossings in 6 seconds in the inner. 
C B A 
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Figure 23-Evaluation of exploratory activity in MeCP2 mice using Open field test. A-C) Analysing the 
exploratory activity in MeCP2 -/y and wt mice, we did not find any significant difference in the time spent 
in external and internal zone between two experimental groups, but we observed in the frequency of 
crossing a significant decrease in male MeCP2 -/y compared to wt mice in the time windows analysed (n=5 
for each group). Significant relative to wt mice * p<0.05. Data were shown as mean ± SEM. 
 
Rett syndrome is classified as an autism spectrum disorders, so we decided to evaluate if 
our mouse model replicates the typical anxiety-like behaviour of these diseases. At this 
purpose, we have evaluated two parameters: rearing, that is the attitude of the animals to 
stay balanced on the hind limbs, and grooming. Mecp2 -/y mice showed a significant 
reduction both in time (two-way ANOVA, genotype effect ### p <0.001, Fig. 24 A) and 
in frequency of rearing compared to wild type animals (fig. 24 B).  
Moreover, Mecp2 -/y mice presented a tendency in increment of grooming time (p = 0.06 
Fig. 24C) and a significant decrease in frequency (two-way ANOVA, genotype effect 
#### p <0.0001, Fig 24D) compared to wild type.  
 
B A 
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Figure 23-Evaluation of anxiety-like behaviour in MeCP2 mice using Open field test. Analysing different 
parameters in open field test as time and frequency spent for rearing (A-B) and time and frequency spent 
for grooming (C-D), we found a significant decrease of time spent for rearing and a tendency to an increase 
of time spent for grooming in male MeCP2 -/y compared to wt mice. (n=5 for each group). For the others 
parameters analysed (panel B-D) we did not find any significant difference between two experimental 
groups. Significant relative to wt mice § p< 0.05. Data were shown as mean ± SEM. 
 
7.3 Characterization of intracellular stress pathway in MeCP2 mouse 
model. 
The most involved brain areas in locomotor activity are the cerebellum and the prefrontal 
cortex. Cerebellum is profoundly involved in motor learning and behaviour, tasks strictly 
connected with synaptic plasticity. The loss of neuronal plasticity and the impairment of 
spines in this structure, can cause extensive damage in motor and cognitive processes. 
Behavioural tests showed in Mecp2 -/y mice showed also an inability to learn and 
memorize the execution of the part of test.  
To investigate the synaptic damage underlying these deficits in RTT syndrome, we 
decided to study neuronal post-synaptic compartment using the TIF fractionation211 of 
B A 
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cerebellum of our animal model. We analysed markers associated with post synaptic 
density, especially subunits of NMDA and AMPA receptors, and the two main scaffold 
proteins of excitatory synapses, PSD-95 and SHANK3.  
We observed a significant increase of NR2A and NR2B subunits levels (t-test, * p <0.05, 
** p <0.01 Fig.) and the same tendency for GluR1 and GluR2 subunits levels of (p = 0.06, 
Fig. 25) in mice Mecp2- / y compared to wild type control. In addition, as a further 
confirmation of the presence of a synaptic damage in the cerebellum, we found a 
significant decrease of the two scaffold proteins of excitatory synapses, PSD-95 and 
Shank 3 (t-test, * p <0.05, ** p <0.01 Fig. 24) in knockout mice compared to their 
respective controls. 
Several evidences in literature have shown a correlation between the synaptic dysfunction 
and the activation of the MAP kinase JNK126,194. Supporting those evidences, our 
laboratory has been extensively studied and characterized JNK and its role in 
neurodegenerative diseases as a key player in synaptic damages. We decided to assess the 
role of MAP kinases JNK in dendritic spine level even in neurodevelopmental diseases 
such as Rett syndrome. 
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Figure 24- Analysis of main post-synaptic receptors in MeCP2 -/y mice vs wt A-B) Western blot analysis 
of NMDA receptors nr2a and nr2b, revealed a significant increase of level of both in male MeCP2 -/y 
compared to wt mice (n=4 for each group). C-D) Western blot analysis of AMPA receptors glur1 and glur2, 
revealed a tendency in increasing. E-F) Psd95 and Shank3 levels are reduced in MeCP2 -/y mice compared 
to wt. Statistical analysis: t-test. Significant relative to wt mice *p< 0.05, ** p<0.01, *** P<0,001. Data 
were shown as mean ± SEM. 
Biochemical analysis of the cerebellar post-synaptic area highlighted an increment 
of JNK phosphorylation in dendritic spines (t-Student, * p <0.05, Fig A) in Mecp2 -
/y compared to wild-type.  
 
Figure 25- Analysis of activation of JNK pathway in MeCP2 -/y mice vs wt A-B) Western blot 
analysis cerebellum revealed a significant increase of JNK phosphorylation, express as P-
JNK/JNK in male MeCP2 -/y compared to wt mice (n=4 for each group). Statistical analysis: t-
test, significant relative to wt mice *p< 0.05. Data were shown as mean ± SEM. 
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As widely characterized, activated kinases act with a cascade mechanism on their targets. 
The elective target of JNK is the nuclear transcription factor, c-Jun. When activated 
through phosphorylation, c-Jun determinates transcription of target genes involved in 
various stress cellular response such as inflammation and neuronal death. We then 
performed Western blot analysis to assess the activation of c-Jun, checking its 
phosphorylated form, P-c-Jun, which was found to increase significantly in mice Mecp2-
/y compared to the wild type control (t-test * p <0.05, Fig.). 
  
Figure 26 -Analysis of JNK pathway in MeCP2 -/y mice vs wt. Western blot analysis of and cerebellum 
revealed a significant increase of P-c-Jun/c-Jun ratio in male MeCP2 -/y compared to wt mice (n=4 for 
each group). Significant relative to wt mice *p< 0.05, *** p<0.001. Data were shown as mean ± SEM. 
 
7.4 Immunohistochemical characterization of MeCP2 mouse model 
In addition to our biochemical analysis, that shown clearly JNK activation in dendritic 
spine and its related pathway, we performed immunohistochemical analysis to make our 
results more consistent. MeCP2 -/y mice cerebellum exhibited activation of the JNK 
signalling with the strong immunoreactivity of its elective target c-Jun (P-c-Jun positive 
staining, panel G-H), confirming biochemical experiments.  Due to the strictly correlation 
between c-Jun phosphorylation and inflammation status212, as well as for the 
inflammatory status reported in RTT disorder213,214  we here also examined the astroglial 
and microglial activation in MeCP2 -/y mice vs wt.  
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We reported an advanced state of inflammation, with overexpression of GFAP, a marker 
of astrogliosys (positive staining in panel A-B-I), as well as the hyperactivation of 
microglia (CD11β positive staining, panel C-D-L), importantly without a reduction of 
neuronal population (NeuN positive staining, panel E-F-M).  
 
Figure 27--Immunohistochemical analysis of cerebellum of MeCP2 -/y compared with wt mice and 
related magnification (40X). A-B) GFAP staining revealed an advanced state of inflammation in ko 
compared to wt mice C-D) CD11β staining revealed a microglia activation in ko compared to wt mice. E-
F) NeuN staining didn’t reveal a reduction of neuronal population in ko compared to wt mice. G-H) P-c-
Jun staining revealed an increase of c-Jun phosphorylation in ko compared to wt mice. I) GFAP 
magnification staining revealed an increment of inflammation state MeCP2 -/y mice with a characteristic 
astrocyte morphology. L) CD11β staining highlighted microglia activation state in MeCP2 -/y 
mice. M) NeuN staining revealed vitality of MeCP2 -/y mice.  Representative sections are shown of 4 
animals used per each group. Scale bar: 100 µm (A-H); 200 µm (I-L-M). 
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7.5 A new strategy to prevent Rett Syndrome: the cell permeable JNK 
inhibitor peptide (D-JNKI1) treatment in MeCP2 mouse model. 
From previous studies conducted in our laboratory, we proved that the inhibition of the 
MAP kinase JNK may contribute to synaptic dysfunction recovery126,215 cognitive and 
motor damage related with neurological diseases 159,216, while the inflammation reduction 
associated with these diseases217,218. 
The cell-permeable peptide D-JNKI1 is able to prevent JNK action on the JBD dependent 
targets, this results in a potent neuroprotection in both acute and chronic injury of the 
CNS. To prove that JNK stress kinase plays a key role in Rett Syndrome, we perform a 
treatment with the cell permeable inhibitor peptide, D-JNKI1, in MeCP2 tm1.1 Bird mouse 
model.   
The summary of the treatment can be seen in fig.32. The mice were intraperitoneally 
injected with D-JNKI1 (22 mg/kg) at the 3rd and 6th week of life, and weekly evaluated 
for well-being parameters (body weight, food and water intake), behavioural tests 
(rotarod and open field test) and finally sacrificed to perform biochemical and 
immunohistochemical analysis at 7 weeks.   
Figure 28-Treatment schedule of D-JNKI1 in MeCP2 mice  
 
According to our previous pharmacokinetic studies153,193,219 the D-JNKI1 administration 
was effectuated with intraperitoneal injection215 (i.p.) every 3 weeks. The peptide is 
stabile for 3 weeks, this long stability is due to its D-amino acidic configuration, the D-
amino acidic are more difficult to degrade by the proteases. 
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7.6 Effect of D-JNKI1 treatment on well-being of MeCP2 mouse model. 
To evaluate the D-JNKI1 effect on this animal model, we analysed the metabolic profile 
by evaluating the growth curves and the consumption of water and food during the entire 
experimental phase. As shown in Fig. 29, we found a significant effect between Mecp2 -
/y males treated and not with the peptide (ANOVA, § p <0.05), with a recovery of body 
weight equal to 10% in treated ko compared to ko and equal 8% in treated wild type 
compared to wild-type, emphasizing the improvement of the health conditions of both 
animals MeCP2- /y that wild type treated with D-JNKI1. (two-way ANOVA, §§ 
treatment effect p< 0.01, Fig.30).  
Figure 29 – Summary and overview of the D-JNKI effect on body weight of MeCP2 mice. D-JNKI1 
administration led to a significant increase of body weight in treated wild type compared to wild type and 
in MeCP2 -/y compared to untreated MeCP2 -/y mice. Statistical analysis: two-way ANOVA, (n=10 for 
each group), treatment effect comparing treated and not treated Mecp2 § P<0,01; genotype effect #### 
P<0,0001). 
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To understand whether the recovery of body weight due to the treatment with D-JNKI1 
could influence the consumption of water and food, we investigated these parameters 
from the first treatment (at 3 weeks of age) until the end of the experiment (7 weeks of 
age). As shown in Fig. 30, MeCP2 -/y treated mice tend to consume more food than the 
untreated (ANOVA, * p <0.05; Fig. 30A), while no differences were found for water 
consumption (Fig. 30B) between the two groups. The obtained data confirm the absence 
of toxic effects due to the treatment, because the peptide treatment determinated a 
recovery of the body weight and the consumption of water and food comparable 
(ANOVA, p §§§§ < 0.0001)  
 Figure 30- Evaluation of food (g) and water (ml) intake pro die. In fig. 30A is show the consumption of 
food for treated MeCP2-/y and untreated ko. We found a similar consumption for both treated and 
untreated mice (n=5 each group). Statistical analysis effectuated: two-way ANOVA. (B) summary for 
consumption recorded for every group in our experiment. (C) water consumption shows a general 
decrement in water consumption by treated and untreated MeCP2 -/y mice, with a general genotype effect. 
(n=5 each group) Statistical analysis effectuated: two-way ANOVA §§§§ P<0,0001 Data were shown as 
mean ± SEM 
 
 
 
 
B A 
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68 
 
7.7 Effect of D-JNKI1 treatment on behavioural performance of MeCP2 mouse model 
The MeCP2 mouse model is mostly characterized by a motor impairment. The 
progressive improvement of well-being during the treatment of Mecp2tm1.1Bird mice 
treated with D-JNKI1 and especially no toxic effect resulting from administration of the 
peptide, we decided to analyse the effect of D-JNKI1 on behavioural deficits associated 
with Rett syndrome. We tested treated and untreated knockout and wild type animals with 
behavioural tests like Rotarod and Open Field Test to evaluate a possible recovery of 
locomotor deficits, explorative and anxious-like behaviours. 
Fig. 31, showed results obtained with the Rotarod tests. Treated Mecp2 -/y mice had a 
significant and progressive recovery of motor skills in compared to Mecp2 -/y mice. In 
fact, the ability to move on the rotating bar is significantly increased at 7 weeks (two-way 
ANOVA treatment effect §§§§ p <0.0001), corresponding to the worse disability in RTT 
of the knockout mice. 
 Figure 31 - Evaluation of D-JNKI1 effect on locomotor activity in MeCP2 mice with Rotarod test. 
MeCP2 -/y mice were found with a significant motor deficit, that was ameliorated by D-JNKI1 
administration: treated Mecp2 -/y performed better than untreated MeCP2 -/y. The increment of latency 
time on the wheel is appreciable 7 weeks of age (n=10 for each group). Statistical analysis: two-way 
ANOVA, genotype effect  #### p<0.0001. post-hoc test: Bonferroni’s multiple comparison, mecp2 -/y vs wt 
** p<0.05, **** p<0.0005, Mecp2 -/y vs D-JNKI1 treated Mecp2 -/y °° p<0.05. Data were shown as mean 
± SEM. 
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To confirm the improvement of locomotor deficits, we decided to test the animals with 
the Open Field Test, analysing the parameters related to locomotor, exploratory activity 
and to anxiety-like behaviour. 
Regarding the locomotor activity, in Fig. 32A we can see a significant increase in the 
average distance travelled by treated Mecp2-/y mice compared to that covered by ko 
untreated animals (two-way ANOVA, §§§§ p <0.0001). We recorded in treated Mecp2-
/y mice an increase of speed (Fig. B; two-way ANOVA, §§§ p <0.001) and, in line with 
the results previously obtained, a decrease in the immobility time (Fig. C; two-way 
ANOVA, §§§ p <0.001) compared to untreated mice, confirming that the locomotor 
deficit and progressive worsening of symptoms in animals with RTT is almost completely 
reverted by the administration of the peptide. In fact, the results obtained show an overall 
improvement in motor performance of the animal treated. This improvement persists for 
the duration of the experimental treatment and goes increasing in time. 
Figure 32 -Evaluation of D-JNKI1 effect on the distance moved in MeCP2 mice using the Open field 
test.  we observed (A) for treated (pink) versus untreated Mecp2 -/y mice (violet), a significant increase in 
D-JNKI1 treated  (n=5 for each group). Statistical analysis: two-way ANOVA treatment effect §§§§ 
p<0.0001. Post-hoc test: Bonferroni’s multiple comparison relative to D-JNKI1 MeCP2 -/y mice vs 
untreated MeCP2 mice, °° p<0.01. ° p<0.05. (B) Summary of distance moved by all considered groups 
Data were shown as mean ± SEM. 
  
A B 
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Figure 33-Evaluation of D-JNKI1 effect on the velocity in MeCP2 mice using the Open field test.  We 
observed (A) for treated (pink) versus untreated Mecp2 -/y mice (violet), a significant ncrease in D-JNKI1 
treated (n=5 for each group). Statistical analysis: two-way ANOVA treatment effect §§§§ p<0.0001. Post-
hoc test: Bonferroni’s multiple comparison relative to D-JNKI1 MeCP2 -/y mice vs untreated MeCP2 mice, 
°°° p<0.001. ° p<0.05. (B) Summary of distance moved by all considered groups. Data were shown as 
mean ± SEM.  
 
Figure 34 -Evaluation of D-JNKI1 effect on the immobile time duration in MeCP2 mice using the Open 
field test.  We observed (A) for treated (pink) versus untreated Mecp2 -/y mice (violet), a significant 
increase in D-JNKI1 treated (n=5 for each group). Statistical analysis: two-way ANOVA treatment effect 
§§§§ p<0.0001. Post-hoc test: Bonferroni’s multiple comparison relative to D-JNKI1 MeCP2 -/y mice vs 
untreated MeCP2 mice, °°° p<0.001. ° p<0.05. (B) Summary of distance moved by all considered groups. 
Data were shown as mean ± SEM. 
 
In the evaluation of the exploratory performance, we considered the time spent in the 
external and in the internal zone, and the frequency with whom mice crossed the arena. 
D-JNKI1 treated compared to untreated MeCP2 -/y mice showed a significant reduction 
in exploration activities, with an increment in the frequency of crossing from the internal 
to external zone (Fig. 35C-D). meanwhile they spent less time in internal zone and 
showed a reduction in the opposite crossing (Fig. 34A-B) in D (ANOVA, p< 0.05).  
A B 
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Figure 35-Evaluation of D-JNKI1 effect on exploratory activity in MeCP2 mice using Open field test. 
Evaluating the time spent in external zone (A-B) in D-JNKI1 treated and untreated MeCP2 -/y mice, we 
found any significant difference between experimental groups in the time windows analysed (n=4 for each 
group). Whereas, the frequency of crossing toward the external zone is affected by a significant difference 
due to the genotype effect (C-D). The statistical analysis: two-way ANOVA § p<0.05. Data were shown as 
mean ± SEM 
Figure 36-Evaluation of D-JNKI1 effect on exploratory activity in MeCP2 mice using Open field test. 
Analysing the D-JNKI1 effect on frequency of entering in internal zone (A-B), we observed a significant 
increase of frequency in D-JNKI1 treated vs untreated MeCP2 -/y mice. Valuating the time spent in internal 
zone (C-D) in D-JNKI1 treated and untreated MeCP2 -/y mice, we found any significant difference between 
experimental groups in the time windows analysed (n=5 for each group). Significant relative to wt mice * 
p<0.05, D-JNKI1 MeCP2 mice vs untreated MeCP2 mice § p<0.05. Data were shown as mean ± SEM. 
 
Concerning the D-JNKI1 effect on anxiety-like behaviour we recorded rearing and 
grooming parameters for MeCP2 -/y mice and D-JNKI1 treated MeCP2 -/y.  We observe 
a significant increase in the time spent for rearing (two-way ANOVA, §§ p <0.01, Fig. 
36A) and a significant increase in the frequency at the 4th week in the treated Mecp2 -/y 
compared to the untreated (Sidak’s multiple comparison * p <0.05). We also observed in 
A B 
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treated animals a reduction of grooming time (p = 0.06 Fig. C) and frequency (ANOVA, 
§§ p <0.01; fig. BD).  
 
Figure 37 -Evaluation of D-JNKI1 effect on anxiety-like behaviour in MeCP2 mice using Open field 
test. D-JNKI1 effect on time spent for and on frequency of rearing. (A), We observed a significant increase 
of time spent in D-JNKI1 treated vs untreated MeCP2 -/y mice (Statistical analysis:two-way ANOVA 
genotype effect §§ p<0.01; post-hoc test: Sidak’s multiple comparison °°p<0.01). Valuating the frequency 
of rearing (C-D) in D-JNKI1 treated and untreated MeCP2 -/y mice, we found a significant difference at 
4th week between experimental groups(n=4 for each group). Significant relative toMeCP2 -/y mice (post-
hoc test: Sidak’s multiple comparison °°p<0.01). Data were shown as mean ± SEM. 
 
Figure 38 -Evaluation of D-JNKI1 effect on anxiety-like behaviour in MeCP2 mice using Open field 
test. Analysing the D-JNKI1 effect on time spent for grooming (A), we found any significant difference 
between experimental groups. Valuating the frequency of grooming (B) in D-JNKI1 treated and untreated 
MeCP2 -/y mice, we observed a significant increase of time spent in treated MeCP2 -/y mice. in the time 
windows analysed (Statistical analysis: two-way ANOVA genotype effect §§ p<0.01; post-hoc test: Sidak’s 
multiple comparison °p<0.05, °°° p<0.001, n=4 for each group). Data are shown as mean ± SEM. 
 
7.8 Biochemical evaluation of D-JNKI1 treatment on MeCP2 mice  
The D-JNKI1 treatment determined an improved metabolic and behavioural profile in 
MeCP2 -/y mice, we here look for a correlation between the peptide effect on JNK 
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signalling and synaptic plasticity focusing on the cerebellum, the area most involved in 
locomotor ability and in synaptic plasticity.  
The D-JNKI1 effect has been investigated with western blot analysing and TIF 
fractionation. 
7.9 JNK signalling and activation. 
As shown before, JNK is activated in post-synaptic density and may have a role in 
neurodevelopmental disorders as a key player in synaptic dysfunction. We checked the 
D-JNKI1 effect on JNK protein of dendritic spine. Biochemical analysis of the cerebellar 
post-synaptic area highlighted a decrement of JNK phosphorylation in treated MeCP2 -
/y compared to MeCP2 -/y. Then we evaluated P-c-Jun/c-Jun ratio (fig. 26), the major 
target of JNK that was significantly increased in cerebellum of MeCP2 -/y compared to 
wt mice (t-test, p< 0.01), indicating a powerful activation of JNK signalling we checked 
if D-JNKI1 treatment prevent JNK action as expected. The D-JNKI1 treatment inhibits 
c-Jun phosphorylation in treated MeCP2 -/y compared to untreated MeCP2 -/y mice (two-
way ANOVA, cerebellum: p< 0.01; fig. 39), the peptide reduces the P-c-Jun/c-Jun ration, 
bringing levels to the control conditions, comparable with wild-type. The JNK signalling 
pathway is powerfully activated in cerebellum and was rescued by D-JNKI1 peptide 
treatment. 
 
Figure 39 -Analysis of D-JNKI1 effect on JNK pathway in MeCP2 mice A-B) The densitometry analysis 
of western blot of whole extract from cerebellum. (A) P-c-Jun/c-Jun ratio revealed a significant decrease 
of c-Jun phosphorylation in D-JNKI1 treated MeCP2 -/y compared to untreated (n=5 for each group). 
Statistical analysis: two-way ANOVA. Post-hoc test: Bonferroni’s multiple comparison, genotype effect 
**p< 0.01, treatment effect §§ p< 0.01. Data were shown as mean ± SEM.  
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To deeper investigate the JNK signalling we investigated also the protein directly 
involved in upstream JNK activation: the MAP kinase kinase MKK4 and MKK7. The 
MKK7 activation was not increased in MeCP2 -/y versus wild type mice. While MKK4 
activation was strong higher, the p-MKK4/MKK4 ratio was significantly increased in 
MeCP2 -/y compared to wt. Importantly this activation was prevented by the D-JNKI1 
treatment, as expected 194, see fig 37. JNK activation is exclusively mediated by MKK4 
and not by MKK7 in treated MeCP2 -/y (Fig. 40 A-B). The D-JNKI1 treatment significant 
decrease levels of P-MKK4 in treated MeCP2 -/y compared to untreated MeCP2 -/y mice 
(ANOVA, cerebellum: p< 0.001, fig. 38C) as expected by the treatment194. 
 
Figure 40 -Analysis of MKK4 and MKK7 signalling and D-JNKKI1 effect in MeCP2 mice. A-B) Western 
blot and relative quantification performed on the total homogenate of male MeCP2 ko and wt mice D-
JNKI1 treated vs untreated. MeCP2 -/y mice showed a significant increase of P-MKK4/MKK4 ratio (A) if 
compared with age-matched wt mice. D-JNKI1 treatment induced a significant reduction of P-
MKK4/MKK4 ratio, while MKK4 total levels are similar between groups (B) (n=5 for each group). 
Evaluating the ratio of P-MKK7/MKK7, (D), levels of P-MKK4 (E) and MKK7 (F), we didn’t find any 
significant D-JNKI1 effect. Significant relative to wt mice *p< 0.05.D-JNKI1 MeCP2 mice vs untreated 
MeCP2 mice §§§ p< 0.001. Data were shown as mean ± SEM  
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7.10 JNK’s role at dendritic spine. 
 MeCP2 -/y mice showed a great activation of JNK in the postsynaptic region (As shown 
in fig. 25), we verified the effect of D-JNKI1 treatment at this cellular level. To 
investigate the effect of JNK inhibition in excitatory synapses of MeCP2 mice we 
analysed the biochemical marker of the PSD region. 
In MeCP2 -/y mice spine presented a decrement of PSD-95 and Shank3 together with an 
increment of AMPA and NMDA receptors. 
The D-JNKI1 treatment bring the NMDA receptors of treated MeCP2 -/y to a normal 
level of wild-type (two-way ANOVA, cerebellum: p< 0.0001; fig. 41A-B), while for 
AMPA receptor subunits levels (GluR1 and GluR2) are not significantly changed by the 
treatment (fig. 41C-D). 
Figure 41-Analysis of JNK signalling and D-JNKI1 effect in MeCP2 mice. A-B) Western blot and relative 
quantification of the TIF fraction of male MeCP2 ko and wt mice. The male MeCP2 -/y mice showed a 
significant increase of NR2A and NR2B subunits of NMDAr if compared with age-matched wt mice. The 
D-JNKI1 treated mice showed a significant reduction of NR2A and NR2B subunits of NMDAr to control 
level of wt mice (n=4 for each group). Statistical analysis: two-way ANOVA, post-hoc test: bonferroni’s 
multiple comparison, significant relative to wt mice ** p>0.001, D-JNKI1 ko treated vs no treated §§§ 
p>0.001 §§§§ P<0,0001.  Data were shown as mean ± SEM 
 
We then study the PSD-95 scaffold protein and its phosphorylation, PSD-95 is an 
important scaffold protein of the PSD region and its alteration is a symptom a dysfunction 
of the post-synaptic element. We found an increment of phosphorylated form of PSD95 
E A 
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in MeCP2 -/y mice, this may indicate a destabilization of mature to immature dendritic 
spines, that was reduced to a level comparable with wt by D-JNKI1 treatment. Instead the 
PSD95 total level decrease in MeCP2 -/y mice, the D-JNKI1 treatment seems to increase 
its level to control mice.  
 
 
 
 
 
Figure 42 -Analysis of D-JNKI1 effect on PSD95 scaffold protein in MeCP2 a significant increase of P-
PSD-95 is visible in MeCP2 -/y compared to wt mice, D-JNKI1 decrease the P-PSD95 level (A, C). While 
MeCP2-/y mice present a decrease level of total PSD-95 compare to wt mice (B, C). The D-JNKI1 stabilizes 
PSD-95 level to wt mice. A significant increase of PSD-95 (B) in D-JNKI1 treated MECP2 compared to 
not treated MeCP2 -/y mice (n=4 for each group). Statistical analysis: two-way ANOVA, post-hoc test: 
Bonferroni’s multiple comparison wt mice *p< 0.05 D-JNKI1 MeCP2 mice vs untreated MeCP2 mice §§ 
p< 0.01, *** p< 0.001. Data were shown as mean ± SEM.  
 
The second important scaffold protein for the organization of excitatory postsynaptic 
densities was Shank3. Levels of Shank3 protein was drastically reduced in MeCP2 -/y 
compare to wt mice (fig 43 A-B). Interestingly the D-JNKI1 treatment could rescue 
Shank3 level and reported it to control condition of wt mice. We detected also RNA 
expression (fig.46 C).  
Figure 43-Analysis of D-JNKI1 effect on SHANK3 scaffold protein in MeCP2. As seen before, a 
significant decrease of SHANK3 is visible in MeCP2 -/y compared to wt mice. D-JNKI1, we found a 
significant increase of shank3 (A, B) in D-JNKI1 treated MECP2 compared to untreated MeCP2 -/y mice 
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(n=4 for each group). Significant relative to wt mice **p< 0.01 D-JNKI1 MeCP2 mice vs untreated MeCP2 
mice §§§ p< 0. 001. Data were shown as mean ± SEM.  
 
The expression analysis of Shank3 (fig. 41C) performed by real time PCR, showed a 
tendence to increase in MeCP2 ko. D-JNKI1 treatment restore the situation taking ko 
levels to the wt.  
 
7.11 D-JNKI1 in MeCP2 mouse model:  immunohistochemical analysis  
The MeCP2 -/y mice exhibited a state of inflammation, hyperactivated microglia we here 
investigated if the D-JNKI1 treatment is able to prevent the inflammation state in the 
brain parenchyma of this RTT mouse model. 
The D-JNKI1 treated mice showed a reduction of inflammation state (GFAP positive 
staining, panel A-B) as well as a reduction of microglia hyperactivation (CD11β positive 
staining, panel C-D), inducting a powerful effect on inflammation. 
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Figure 44 - Immunoistochemical analysis of D-JNKI1 effect in cerebellum of wild type, MeCP2 -/y and 
treated MeCP2 -/y mice. A-B-C) GFAP staining revealed an advanced state of inflammation in D-JNKI 
treated ko compared to wt mice. D-E-F) CD11β staining revealed a microglial de-activation in ko 
compared to wt mice, resolved by D-JNKI1 treatment. G-H-I) NeuN staining revealed a similar situation 
for the three-considered group, with no reduction of neuronal population. L-M-N) P-c-Jun staining 
revealed an increase of c-Jun phosphorylation in ko compared to wt mice. Representative sections are 
shown of 4 animals used per each group. Scale bar: 100 µm. 
 
We also analysed the effect of D-JNKI1 on survival of the neuronal population in treated 
versus and the untreated mice: the inhibition of JNK prevents death and promote survival, 
in fact we showed an increasing in neuronal population (Neun positive staining, panel E-
F) and this is directly correlated the decrease of P- c-Jun staining treated mice compared 
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to untreated (P-C-Jun positive staining, panel G-H), confirming the D-JNKI1 is inhibiting 
JNK action on its elective target, c-Jun. 
Figure 45- Magnification (40X) of immunohistochemical analysis of D-JNKI1 effect in cerebellum of 
MeCP2 -/ymice.  A-B) GFAP staining revealed a recovery of inflammation state in D-JNKI1treated mecp2 
compared to mecp2 untreated mice .C-D) CD11β staining revealed a reduction of microglia activation 
in D-JNKI1 treated MeCP2 -/y compared to MeCP2 -/y untreated mice. E-F) NeuN staining revealed the 
same neuronal population in D-JNKI1 treated mecp2 compared to mecp2 untreated mice.  
 
7.12 Biochemical evaluation of D-JNKI1 effect on inflammation in MeCP2 mouse 
model. 
Activation of c-Jun led to the transcription of molecules involved in inflammatory 
response and in neuronal toxicity. Many studies reported an accumulation of glutamate 
in synaptic region of RTT mouse model, that can overstimulate neurons to an 
inflammatory response. We investigated inflammatory state of these mice by analysing 
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astrocytes and microglia reactivity, studying GFAP (astroglial marker) and IBA-1 
(microglial marker).  
Figure 46-Analysis of D-JNKI1 effect on GFAP in MeCP2 mice. (A) densitometry of GFAP in MeCP2 
mice. We see a significant increment of the GFAP protein level in MeCP2 -/y compared to wt mice. D-
JNKI1 treatment led GFAP level of MeCP2 -/y comparable to a wt condition (n=4 for each group) (C) real 
time of GFAP expression is in line with western blot results treated MECP2 increased GFAP expression 
and compared to wt and D-JNKI1 treatment of MeCP2 -/y mice powerfully reduce its level.   (n=3 for each 
group). Statistical analisys: two-way ANOVA Significant relative to wt mice ***p< 0.001 D-JNKI1 
MeCP2 mice vs untreated MeCP2 mice § p< 0.05. Data were shown as mean ± SEM.  
 
 
Figure 47 -Analysis of D-JNKI1 effect on microglyosis in MeCP2 mice. We see a significant increment 
of the protein level in MeCP2 -/y compared to wt mice (A, B). D-JNKI1 Treatment led MeCP2 -/y to a wt 
condition (n=4 for each group) (C) real time of IBA-1 expression is in line with western blot results treated 
MECP2 compared to not treated MeCP2 -/y mice (n=3 for each group). (D) RNA expression of C1qa, a 
marker of whole microglia, activated or not. We didn’t see differences in every analysed group, that 
correspond to the same cell number in every brain.  Statistical analysis: two-way ANOVA Significant 
relative to wt mice ***p< 0.001 D-JNKI1 MeCP2 -/y mice vs untreated MeCP2 mice § p< 0.05. Data 
were shown as mean ± SEM.  
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To highlight the microglia reactivity in MeCP2 -/y mice, we first analysed the most 
important microglial markers, IBA-1 with western blot and real time PCR. MeCP2 -/y 
mice had a significant decrement of IBA-1 protein level as well as expression level 
compared with wt mice. The D-JNKI1 treatment partially prevented the IBA-1 decrease 
while completely inhibited the expression level drop. 
 To be sure that IBA-1 level does not depend from the cell number, we evaluated the 
expression of C1qA gene, but we found an equal expression in wt, treated and untreated 
MeCP2 -/y; we thus are more confident that suggest that the changes of microglia are 
correlated with this pathological state.  
 
7.13 JNK pathway in a translational model: IPSCS from RETT HUMAN girl 
deriving from fibroblasts. 
In collaboration with the Prof. Renieri’s laboratory (University of Siena), we analysed the 
JNK signalling in the IPSCs cell, that are induced pluripotent stem cells, derived from 
human fibroblast of Rett patience. After differentiation in pyramidal neurons (fig 49B), 
cells were treated with the D-JNKI1, and then were used for biochemical analysis. As 
shown in fig.49 C-D, the Rett allele of clone R301C of the patience that expressed the 
mutated MeCP2 presented an increased P-C-Jun/c-Jun ratio compared to the allele 
without mutation, expressing the normal MeCP2 of the same R301C of the patience that 
is expressing the normal gene. Importantly to our aim, the D-JNKI1 treatment strongly 
decrease c-Jun phosphorylation, indicated as a ratio (P-C-Jun/c-Jun). This experiments 
are still in progress. Moreover, we performed an LDH assay to evaluate cell well-being 
after treatment and we found a significant increment of LDH levels in mutated cells and 
a rescue in treated mutated cells. 
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Figure 48-Analysis of D-JNKI1 effect on JNK pathway in MeCP2 mice. (A) imaging of IPS cells take 
before the differentiation and induced neuron. Morphology is too different between these two kinds of cells 
(B-C) western blot analysis of cells confirmed what we saw in animals: we found an activation of c-Jun 
and in the same time comparing wt with ko, and a rescue with D-JNKI1 treatment comparing ko with 
treated ko. (n=1 for wt and treated wt; n=2 for ko and treated ko. Statistical analysis no possible. Data 
were shown as mean ± SEM.  
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6.  Discussion 
Rett syndrome (RTT) is a severe neurological disease X-linked, with an incidence of 
1:10000 children almost exclusively female. The syndrome is included in ASD, autistic 
spectre disorders. In more than 90% of the cases, Rett syndrome is caused by mutations 
of MECP2 gene, encoding the methyl-CpG binding protein 2. The clinical course of the 
Rett syndrome and the severity are different among girls affected by this disorder, ranging 
from a mild to a severe phenotype, because of random X-inactivation54. RTT onset is 
characterized by a normal development, followed by the appearance of cognitive 
impairment, autism-like bahaviour and the progressive loss of acquired skills, such as 
verbal communication, using purposive of the hands and ambulation. This phenotypic 
variability was reproduced in many different mouse models. In 2011, a workshop was 
organized to evaluate the variability in the genetic of MeCP2 mutant mice, the 
methodologies used by the laboratories to produce and to analyse data and to define the 
physiological and behavioural phenotypes of the different mouse models which were 
considered more or less closer to the clinical observations in Rett human individuals. The 
aim of the workshop was to define the aspects in different mouse models which were 
important for preclinical studies of the Rett syndrome. The participants observed that in 
particular,MeCP2 Bird and Jaenish (deficient mice), showed a marked reduction in brain 
size with alterations in neuronal morphology and a quite reproducible variation in 
respiratory and cardiac activities. Thus, in this project, we decided to use MeCP2 tm 1.1 
Bird mice, the mouse model that presents the most significant alterations in brain weight, 
volumes of cortex and cerebellum than those observed, for example, in the Jaenisch 
strain120,220. In addition, these alterations in cortical morphology in MeCP2 mice are 
highly reproducible and closely resemble those observed in patients thus, they are 
considered strong evidence of face validity of these Rett mouse models221. 
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MeCP2 is found in a wide variety of tissues, but is most abundant in the brain. A 
quantitative survey normalized against cytoplasmic proteins suggested that lung and 
spleen are also MeCP2-riched tissues59. Direct quantification in adult mouse brain has 
estimated 16 million molecules of MeCP2 per nucleus in neurons with almost an order of 
magnitude less in glial cells and 30-fold less in liver cells222. The neuronal MeCP2 level 
is relatively low at birth but, in the mouse, increases greatly during the first 3 weeks of 
life before reaching a plateau115,222. Because neurogenesis is largely complete before 
birth, the increase is due to the upregulation of MeCP2 expression within a constant 
number of neurons. These neurons are, however, developmentally active, undergoing 
synaptogenesis at this time. 
In addition, MeCP2 has a role in post-mitotic neurons, where is involved in the 
maintenance processes. A Rett brain, in fact, is characterized by neurons with smaller 
dimensions and a high degree of packing without neuronal death, despite this, neurons 
show dysfunctionality. MeCP2 deficiency affects the brain and the mechanism of this 
alteration are poorly understood and are the subject of intense research. Progresses are 
being made on all these fronts4,223–225, but as things stand, a definitive molecular 
pathology of RTT remains elusive. 
In this project, we studied MeCP2 tm 1.1 bird male mice valuating general wellbeing 
conditions, biochemical alterations of spine, neuronal morphology, locomotor and 
exploratory functions; in this context, we analysed also the JNK’s role in Rett syndrome 
because previous studies of our laboratory showed its involvement in disease 
characterized by synaptopathology.  
Since today still there are no treatments to cure or slow RTT, we also evaluated the effects 
of JNK’s inhibition with a well-characterized cell-permeable peptide, the JNK inhibitor 
peptide (D-JNKI1) and we found that this treatment significantly improved the general 
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health and rescued behavioural impairments as well as synaptic dysfunctions in this 
mouse model. The male mouse model, chosen for our evaluations, are hemizygous for 
MeCP2 and manifest the pathological symptoms already at 3 weeks of age and 
progressively until their deaths (9 -10 weeks). Whereas female mice (MeCP2 +/-) are 
heterozygous for the deletion and similarly to humans, have an X-random inactivation. 
This random inactivation mirrors the mosaicism and the great variability of symptoms; 
furthermore, they have a delayed onset and don’t show a progressive pathology.  
Despite the difficulties to amplify and to breed colony, we started our studies on male 
hemizygous mice (MeCP2 -/y) because of their homogenous phenotype and for the 
possibility to treat them for a shorter period of time in addition the proof of concept of 
the neuroprotective D-JNKI1 effect in a more severe phenotype is an add value to for the 
potential therapeutic approach. In fact, we think that if D-JNKI1 show to prevent or to 
slow down the most severe RTT phenotype of MeCP2 -/y mice, it will be powerful in a 
less severe phenotype (female MeCP2 +/-) and even more protective.  
The intracellular pathways related to Rett-pathological mechanisms are largely unknown; 
we here investigated the c-Jun N-terminal protein kinase (JNK) pathway in this RTT 
mouse model. We showed that JNK plays an important role in MeCP2 -/y Bird model. 
These results represent the proof-of-principle of JNK activation in RTT. Importantly, 
RTT is a pathology involving neuronal dysfunctionality and JNK is strongly implicated 
in both synaptic injury as well as plasticity in the CNS. Furthermore, JNK is a pivotal 
player in mediating many different brain-stress signal pathways, in fact is implicated in 
apoptosis, oxidative stress, neuronal degeneration and inflammation, all conditions 
related to RTT. Our results proved the significant increment of the ratio of P-c-Jun/c-Jun 
in MeCP2 Bird mouse model in more affected brain areas as cerebellum, hippocampus 
and cerebral cortex (results not shown for hippocampus and cortex). Importantly, JNK 
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protein kinase is not just a well-known key player in response to acute and chronic stress 
in the CNS and is strongly involved in plasticity/synaptopathy in neurodegenerative 
diseases126,226,216. 
The over-phosphorylation of c-Jun underlines a strong activation of the JNK signalling 
pathway in the nucleus, which led to transcription of proteins involved in many different 
processes like for instance synaptopathology, axonal grow and dendrite branching, 
inflammation as well as neuronal death. Moreover, immunohistochemical studies 
effectuated on brain of MeCP2-/y mice by other groups, demonstrated that pyramidal 
neurons exhibit a reduction of the soma area, the diameter of the proximal dendrite on the 
first branch and the diameter of the distal dendrite at 100 μm from the soma. Sholl’ 
analysis revealed also a reduction in the apical dendritic arborization in MeCP2-/y 
mice115,116. 
Anatomically, MeCP2 deficiency causes reduced brain size. This may be due to size 
decreases in major brain regions such as the frontal and temporal lobes, caudate nucleus, 
thalamus, midbrain, and cerebellum, all of which have been documented in RTT 
patients121,227–229. At cellular level, the neuronal soma is smaller in the absence of MeCP2, 
and cells are more densely packed57,109,230. More specific abnormalities have been 
observed at the synapses: post-mortem brain samples from RTT patients and MeCP2-
deficient mice present postsynaptic morphological defects such as reduced dendritic spine 
density and alterations in spine morphology57,104–106,115,116,120,229,231. At pre-synaptic sites, 
the lack of MeCP2 is associated with an abnormal number of axons120 and a defect in 
axonal targeting120,232,233. These results imply a decrease in the number of synapses in 
RTT brains, which has been confirmed for glutamatergic synapses in primary neuronal 
cultures27. Overall, the structural defects described at the synapse may suggest that the 
loss of MeCP2 triggers alterations in the functioning of the synapses and, consequently, 
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of the neuronal networks. However, morphological analyses have focused on neurons and 
specific cerebral regions, namely the hippocampus and various cortical regions. 
Therefore, even though it is tempting to assume that the morphological defects described 
are the same throughout the entire brain, all major brain regions have not been studied 
systematically. Analysis of neurotransmission associated with loss of MeCP2 provides 
further evidence for synapse dysfunction. Post-mortem analysis in RTT brains showed 
altered levels of neurotransmitters such as glutamate and biogenic amines as well as 
changes in the abundance of some neurotransmitter receptors. Several studies contradict 
these results, however229,234. These discrepancies may be due to technical issues 
associated with human post-mortem brain analysis. In mice, reduced levels of serotonin 
(5-hydroxytryptamine), adrenaline, and dopamine have been found in the Mecp2-null 
brain235–238. These are associated with regional defects in the expression of key rate-
limiting enzymes tyrosine hydroxylase and tryptophan hydroxylase 2 in the brainstem, 
the substantia nigra, and the raphe nuclei 230,236,239. Analysis of spontaneous miniature 
excitatory and inhibitory postsynaptic currents indicated a shift in the 
excitatory/inhibitory (E/I) balance, with increased excitatory and decreased inhibitory 
neurotransmission in the hippocampus and cortex28,29,34,240,241. This is supported by data 
showing pre- and post-synaptic defects of GABA-ergic, and therefore inhibitory, 
neurotransmission in the brainstem242. Consistent with the idea of disturbance of the E/I 
balance, long-term potentiation (LTP) is also altered in the hippocampus of symptomatic 
MeCP2-deficient mice61,118,243. These data, added to the morphological studies, imply that 
loss of MeCP2 causes malfunction of numerous synapses throughout the brain, which 
creates less efficient neuronal networks and gives rise to RTT-like phenotypes. 
Unfortunately, the MeCP2 mutant mice behavioural phenotypes are far from Rett 
patients, for instance the typical human cognitive disability. In MeCP2 mice model, motor 
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impairments are described and in the Open field and elevated plus maze test revealed an 
anxiety behaviour in 4 week-old MeCP2-/y Bird mice244.  
In our study, performing Rotarod and Open field tests, we observed a strong reduction of 
locomotor performances in Mecp2 -/y compared to wt mice.  
Taken together, latency time on rotarod, distance moved, velocity and immobility 
parameters, highlighted that motor impairment is severe and debilitating and get worst 
during time progression of the pathology.  From these results, we showed that the major 
hallmark of this mouse model is locomotor impairment, but they showed also an anxiety 
behaviour, these results will probably become more consistent by increasing the number 
of mice analysed. In accordance with us, Bittolo et al. found that both in open field and 
elevated plus maze tests, MeCP2-/y mice had a reduced motility, a reduced rearing and 
grooming activity245.  
The brain areas most involved in locomotor activity are cortex and cerebellum. To detect 
a correlation between behavioural impairment and synaptic dysfunction, we investigate 
the JNK role in these regions. 
We studied JNK activation at the spine level, by using the TIF fractionation, we detected 
a powerful JNK activation in the post-synaptic element. The JNK role at the spine level 
has been previously proved in AD synaptopathy126,127,226and we here confirmed the 
correlation between P-JNK increase and the biochemical alterations of the PSD. 
To define JNK action at this level focusing on important post-synaptic receptors, AMPA 
and NMDA, and two important scaffold proteins PSD-95 and SHANK3 of the PSD 
region. While the nr2a and nr2b as well as glur1 and glur2 levels significate increased, 
the scaffold proteins decreased. Scaffold proteins link directly or indirectly the receptor 
and take them up at the membrane level of the PSD region, favouring plasticity. The 
NMDA and AMPA receptor level increment and the PSD95 and SHANK3 level 
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decrement can be related to the synaptic dysfunction phenomenon, in which receptors are 
in the right place without an efficacy link to the scaffold proteins that make them not 
normally functioning and JNK is strongly activated as well at the post-synaptic element.  
However, biochemical marker changes in the PSD region of Mecp2 -/y can reasonably 
be expected due to the impaired neuronal function of these mice. These data seem to be 
in agreement with a study that proved an altered dynamics of spine and dendritic filopodia 
during development, which hinders the correct formation and the plasticity of synapses 
in MeCP2 mice113. Moreover, the deficit in spine stabilization in MeCP2 mice was also 
confirmed by a reduction in levels of PSD95 expression compared to wild-type mice113. 
The short-time structural plasticity of dendritic spines is altered in a model of Rett 
syndrome.  We confirmed with immunohistochemical analysis that c-Jun is strongly 
activated in MeCP2 -/y compared to wild type mice. The c-Jun staining is usually related 
to neuronal death pathway, we therefore checked using NeuN, a marker of neuronal 
vitality, to verify eventually differences in neuronal population between wt and ko. No 
signs of neuronal death have been detected in cerebellum. However, c-Jun is also 
implicated in the inflammatory pathway and we look for an inflammatory response in 
Rett brain analysing astroglial and microglial response/reaction. The astroglial activation 
was finally detected in Mecp2 -/y mice. Furthermore, individuals with RTT have 
increased expression of glial fibrillary acidic protein (GFAP)246, an intermediate filament 
protein family that is predominantly expressed in astrocytes within the CNS247,248 While 
it is well-defined that GFAP within astrocytes plays an important structural role, it is also 
becoming clear that GFAP is also important for synaptic plasticity, vesicular transport of 
neurochemicals and responses to injury249. More importantly, atypical expression of 
GFAP has been observed in numerous mental health diseases and increased expression 
of GFAP in mice causes a lethal astrocyte dysfunction250. Taken together, these data 
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suggest that tight control of GFAP expression may be necessary for normal brain 
development and function. In fact, the restoration of MeCP2 in glial cells can reverse 
some RTT symptoms in mice that have a mutation in MeCP235.  
This strongly supports the idea that GLIA plays an important role in Rett Syndrome. 
Many evidences in literature had shown that astrogliosis is associated to microgliosis, 
thus we decided to investigate this correlation using the CD11β, a markers of activated 
microglia, and we found that Mecp2 -/y presented a strong activation compare to wt mice. 
Further investigations are needed to clarify this aspect. However, the role of microglia as 
sensors of pre- and post-natal environmental stimuli and its involvement in the regulation 
of synaptic connectivity, maturation of brain circuitry and neurogenesis has recently 
emerged251,252. The immune dysregulation has been found in children with Fragile X 
syndrome and an intrinsic microglia dysfunction has been recently reported in Rett 
syndrome253. 
At present, there is no cure for the Rett syndrome. Some approaches tried to reverse the 
symptoms of this disorder starting from the reactivation of MECP2 gene or through 
reactivation of the normal allele58. An alternative approach to rescue the Rett phenotype 
is to act on the factors that are downstream of MeCP2 function through a pharmacological 
treatment. These factors include neurotrophins (like BDNF or IGF-1) and 
neurotransmitters (like noradrenaline, serotonin and dopamine). A deficit in monoamine 
levels, including noradrenaline, serotonin and dopamine was reported in the brain and 
cerebrospinal fluid of both Rett patients and MeCP2-/y mice235. 
Previously studies of our laboratory widely showed that, D-JNKI1, by preventing JNK 
action, was able to inhibit neuronal degeneration in both acute and chronic brain damage.  
We here test the D-JNKI1 against Rett syndrome symptomatology. The treatment started 
at the 3rd week of life, in an asymptomatic state, in wild-type and Mecp2 -/y mice until 
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the 7rd week of life; then we evaluated the effect of the peptide on wellbeing conditions 
(body weight, food and water consumption, survival rate), motor and exploratory 
performance, synaptopathy and brain parenchyma inflammation.  
The ability of D-JNKI1 to chronically inhibit c-Jun phosphorylation in vivo was assessed 
by Western Blotting and immunoreaction in Rett mouse model. As expected, D-JNKI1 
strongly prevented c-Jun activation. Interestingly D-JNKI1 treatment reduces this c-Jun 
activation to a level comparable to the one observed in wt mice. These results underline 
that D-JNKI1 is able to prevents JNK’s action on its elective target and the peptide is 
working as expected133,159,219,226,216,254.  
Our findings corroborate the concept that JNK plays a critical role in the Rett 
neurodegenerative process. The treatment with the peptide, by preventing JNK action, 
increase significantly the body weight, underling the protective effect on wellbeing of the 
severe phenotype of Mecp2 -/y. Importantly this is correlated to an improvement also in 
motor and cognitive performance of treated Mecp2 -/y. 
Valuating the D-JNKI1 effect on behavioural performance of Mecp2 -/y mice, we 
observed the recovery of a locomotor performance in the rotarod test, and in the rescue 
of the exploratory behaviour in the open field test. The evident reduction of the time spent 
in immobile condition correlated to a rescue of locomotor and coordination abilities in 
the animals treated with D-JNKI1 could be due to a neuroprotective effect of the 
treatment. 
The treatment underlines for the first time the therapeutic potential of JNK inhibitory 
treatment against Rett pathology. Indeed, we here show that D-JNKI specific JNK 
inhibition promotes functional recovery of Rett behavioural impairment, by inhibition of 
c-Jun and these changes are accompanied by an increase in motor and cognitive 
performances. Investigating more in detail the JNK pathway and the relationship among 
92 
 
MKK4 and MKK7, that play different functions in the JNK signal transduction pathway, 
we found a strong activation of P-MKK4/MKK4 ratio, while P-MKK7/MKK7 was 
unchanged this indicated that the upstream activator of JNK is just MKK4 and the 
treatment with the peptide prevented MKK4 activation as well as c-Jun phosphorylation. 
Consequently, D-JNKI1 acts downstream JNK by preventing its action on targets and in 
the same time, upstream inhibiting its upstream activator MKK4.  
D-JNKI1 was administrated 3rd week after the first spine alteration and we used a "post-
symptomatic" treatment since it is clinically more relevant. The fact that the treatment 
reverted the behavioural defects suggest, as previously demonstrated, that it acts at the 
spine level and rescue synapsis dysfunction. In AD synaptopathy the JNK inhibitor 
peptide prevented the biochemical alterations of the PSD226,216. Here the treatment 
increased the NMDA receptors as well as PSD95 levels while it is ineffective on AMPA 
receptor. D-JNKI1 counteracts partially the biochemical changes in the PSD regions of 
Mecp2 -/y. Since RTT is an autistic spectrum disorder (ASD), we decided to investigate 
also another SAP that would be implicated in synaptic function. SHANK3 (SH3 and 
multiple ankyrin repeat domain 3) is a member of the highly conserved Shank/ProSAP 
family of synaptic scaffolding proteins. In addition, SHANK3 is suggested as a strong 
candidate gene for the pathogenesis of Autism and its loss results in disruption of synaptic 
function255. In fact, shank is major components of the excitatory postsynaptic 
density101,256. It is probably implicated in synaptic abnormality during neuronal 
development. Dysregulation of Shank3 leads to alterations in spine morphogenesis, 
shape, and activity of the synapse via altering actin dynamics257. The Shank3 levels 
drastically drop in Mecp2 -/y mice, this collapse may be responsible for abnormal spine 
formation and plasticity. The rescue with D-JNKI1 treatment is important because it 
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determinate a restoration of Shank3 levels and its functionality at the PSD region, but 
further study in this direction will be necessary. 
Different monogenic diseases included into ASD as Rett syndrome (RTT), Fragile X 
syndrome, and SHANK3 gene deficiency (Phelan-Mc Dermic syndrome) are commonly 
related to synaptic and immune function258. These diseases although caused by different 
mechanisms share the same pathology at the cellular and molecular levels. Common 
pathological processes in central nervous system (CNS) disorders involve inflammation 
of the brain, abnormal microglial function and synaptic dysfunction, 
Since we observed a c-Jun activation, astrogliosis and activated microglia in Mecp2 -/y 
mice, we analysed whether D-JNKI1 inhibition could have a protective effect on these 
two types of inflammatory responses.  
The biochemical analysis had revealed a protective effect of D-JNKI1 on synaptic 
dysfunction, and the immunoistochemical analysis of cerebellum and brain parenchyma 
revealed that P-c-Jun staining link to astrogliosis and activated microglia both in cortex 
and cerebellum of Mecp2 -/y mice. In fact, the p-c-Jun, GFAP and CD11β staining was 
reduced in Mecp2 -/y treated compared to untreated mice, indicating a powerful effect of 
D-JNKI1 on in our experimental model. Many evidences in literature had reported altered 
microglial function in Rett syndrome 37,43,259,260. In fact, neuron-only expression of normal 
MeCP2 was not sufficient to reverse the Rett phenotype in mice; instead brain-wide 
expression was needed suggesting the importance of glia cells, astrocytes or some other 
brain cell type61. According to our results, it was found also increased glia neurodensity 
in Rett syndrome suggesting inflammatory astrocytosis234, underlying the importance of 
D-JNKI1 effect to counteract this important pathological aspect. 
Biochemical data obtained with western blot analysis had confirmed D-JNKI1 protective 
effect both in cortex and cerebellum of Mecp2 -/y mice.  
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Since CD11β is a marker of whole microglia, it is not easily detectable with western blot, 
to investigate microglia, we checked its activation by study the IBA-1 protein level and 
relative RNA expression, and we found in both cases a reduction of levels in Mecp2 
untreated mice. So microglia seem to be less reactivity in Mecp2 -/y compared to wild-
type mice, assuming that it could be related to the microglial total cell number. Thus we 
decided to value the C1qa expression, a marker that detects all microglial population and 
we don’t find any differences among experimental groups. Summarizing the data 
obtained from these analyses, we concluded that the number of microglial cells in the 
brain are similar in every case, so Mecp2 -/y cells are less reactive then the wild-type 
mice. Anyway, we observed a protective D-JNKI1 effect detected by a recovery of IBA-
1levels in treated Mecp2 mice. However further experiment will be done to clarify this 
issue.  
While concerning neuronal death, since valuating the neuronal population with NeuN, a 
marker of neuronal vitality, we didn’t found differences between wt and Mecp2 -/y mice, 
consequently we decided to not investigate the D-JNKI1 effect against neuronal death.  
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CONCLUSIONS 
 
Our work underlines the key role of JNK pathway never reported before in Rett syndrome, 
and the importance of D-JNKI1 treatment in MeCP2-/y mice to restore the main 
symptoms, in particular the general well-being, synaptic dysfunction and the correlated 
behavioural impairments as well as inflammation generated by astrogliosis and 
microgliosis. However, other studies are necessary to understand the role of JNK, firstly 
in heterozygous female MeCP2 mice that show a less severe symptomatology compared 
to male mice, but replicate exactly the genetic mutations as human female RTT patients. 
Subsequently, we will investigate the D-JNKI1 effect on female MeCP2 mice, 
performing also EM ultrastructural observations to better analyse the synaptic 
dysfunction and the recovery associated to the treatment. Moreover, our preliminary data 
on hIPS cells showed the same activated pathway detected in the used mice model and a 
rescue by D-JNKI1 treatment. Obviously, the unexpected enrolment of JNK pathway in 
RTT syndrome open a way for transnationality of this study, but we have to deepen the 
effective role of JNK’s pathway in mutated human cells. 
In conclusion, we believe that we provide the first proof of the key role of JNK in RTT 
and more importantly that the manipulation of JNK pathway may represent the 
development of an innovative strategy to tackle Rett Syndrome, providing a real chance 
of cure for patients being D-JNKI1 already in phase III clinical trials (see AM-111 
(AurisMedical) and XG102 (Xigen) produced by two biopharmaceutical companies. Both 
AM-111 and XG102 are already in phase II & III clinical trials, 
http://www.xigenpharma.com/clinical-trials and http://www.aurismedical.com/product-
candidates/pipeline).  
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